pamidronate has been researched along with Age-Related Osteoporosis in 183 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Zoledronic acid is at least as effective as pamidronate as treatment for paediatric osteoporosis, and has a similar safety profile." | 9.14 | Safety and efficacy of intravenous zoledronic acid in paediatric osteoporosis. ( Brown, JJ; Zacharin, MR, 2009) |
| "We aimed to determine the efficacy and safety of a cyclic intravenous therapy with pamidronate in patients with postmenopausal or glucocorticoid-induced osteoporosis." | 9.11 | Pamidronate increases bone mineral density in women with postmenopausal or steroid-induced osteoporosis. ( Cauza, E; Dunky, A; Etemad, M; Hanusch-Enserer, H; Hanusch-Enserer, U; Noske, H; Partsch, G; Winkler, F, 2004) |
| "5) nonambulatory children with cerebral palsy or a neuromuscular disorder received cyclic intravenous administration of pamidronate." | 9.11 | Cyclic administration of pamidronate to treat osteoporosis in children with cerebral palsy or a neuromuscular disorder: a clinical study. ( Allington, N; Gerard, P; Vivegnis, D, 2005) |
| "The efficacy and safety of oral pamidronate was examined in a double-blind, placebo-controlled trial in women and men with established osteoporosis." | 9.10 | Daily oral pamidronate in women and men with osteoporosis: a 3-year randomized placebo-controlled clinical trial with a 2-year open extension. ( Brumsen, C; Geelhoed-Duijvestijn, PH; Hamdy, NA; Landman, JO; Lips, P; McCloskey, EV; Netelenbos, JC; Papapoulos, SE; Pauwels, EK; Roos, JC; Valentijn, RM; Zwinderman, AH, 2002) |
| "The effect of pamidronate therapy on bone histology was studied in patients with osteoporosis with at least one vertebral fracture in a randomized, double-masked, placebo-controlled, multi-center trial." | 9.09 | Bone histomorphometric evaluation of pamidronate treatment in clinically manifest osteoporosis. ( Bravenboer, N; Hamdy, NA; Holzmann, P; Lips, P; Netelenbos, JC; Papapoulos, SE, 1999) |
| "The effect of oral pamidronate on bone mineral density and its adverse effect profile was investigated by a double-masked placebo-controlled study of 122 patients aged 55-75 years with established vertebral osteoporosis." | 9.09 | Intermittent oral disodium pamidronate in established osteoporosis: a 2 year double-masked placebo-controlled study of efficacy and safety. ( Blake, GM; Davie, M; Fogelman, I; Gibson, T; Haddaway, M; Ryan, PJ, 2000) |
| " Irrespective of the mode of osteoporosis prevention, osteocalcin levels increased whereas urinary deoxypyridinoline decreased after transplantation, and significant bone loss was observed in both treatment groups." | 9.09 | Prevention of osteoporosis in heart transplant recipients: a comparison of calcitriol with calcitonin and pamidronate. ( Bianda, T; Brunner, H; Junga, G; Kiowski, W; Linka, A; Schmid, C; Steinert, H, 2000) |
| "The aim of this study was to compare the action of two regimens of intravenous (iv) pamidronate in the primary prevention of glucocorticoid-induced osteoporosis (GC-OP)." | 9.09 | Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone. ( Boutsen, Y; Devogelaer, JP; Esselinckx, W; Jamart, J, 2001) |
| " administration of disodium pamidronate can effectively achieve primary prevention of glucocorticoid-induced osteoporosis (GIOP)." | 9.08 | Primary prevention of glucocorticoid-induced osteoporosis with intermittent intravenous pamidronate: a randomized trial. ( Boutsen, Y; Devogelaer, JP; Esselinckx, W; Jamart, J; Stoffel, M, 1997) |
| "To explore the effects of pamidronate disodium combined with calcium on BMD values and the severity of pain in elderly patients with osteoporosis based on the mobile terminal platform for the Internet of Things." | 8.12 | Effects of Pamidronate Disodium Combined with Calcium on BMD Values and Severity of Pain in Elderly Patients with Osteoporosis Based on Mobile Terminal Platform for Internet of Things. ( Bai, Z; Guo, P; Kang, M; Wang, D; Wang, J, 2022) |
| " Here, a case of a 9-year-old girl with familial HCS and multiple spinal fractures, who has been effectively treated with pamidronate, is presented." | 7.78 | Two-year cyclic infusion of pamidronate improves bone mass density and eliminates risk of fractures in a girl with osteoporosis due to Hajdu-Cheney syndrome. ( Galli-Tsinopoulou, A; Giannopoulou, EZ; Giza, S; Kyrgios, I; Laliotis, N; Maggana, I, 2012) |
| "The aim of this study was to evaluate a possible role of microcracks in the pathogenesis of bisphosphonate-related osteonecrosis of the jaw (ONJ) and to discuss an etiological model." | 7.76 | Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: a possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings. ( Eufinger, H; Hoefert, S; Schmitz, I; Tannapfel, A, 2010) |
| "To analyze the effects of intravenous pamidronate (APD) on bone remodelling, bone mineral density (BMD), fractures and bone mineral metabolism parameters, and the rate of adverse events, with special attention to renal function, in patients with osteoporosis with intolerance and/or any contraindication to oral bisphosphonates." | 7.76 | Effects of intravenous pamidronate on renal function, bone mineral metabolism and bone mass in patients with severe osteoporosis. ( Gifre, L; Guañabens, N; Hernández, MV; Monegal, A; Muxi, A; Peris, P; Reyes, R, 2010) |
| "We report on our experience with 13 cases of jaw osteonecrosis in patients treated with amino-bisphosphonates." | 7.74 | Thirteen cases of jaw osteonecrosis in patients on bisphosphonate therapy. ( Bonneterre, J; Cortet, B; Facon, T; Maes, JM; Magro, L; Penel, G; Vieillard, MH, 2008) |
| "Intravenous pamidronate is frequently used for the treatment of osteoporosis in patients who cannot tolerate oral bisphosphonates." | 7.73 | The effect of intravenous pamidronate versus oral alendronate on bone mineral density in patients with osteoporosis. ( Bultink, IE; Dijkmans, BA; Lems, WF; Vis, M, 2005) |
| "We conducted a retrospective study of 26 patients treated with intermittent, intravenous pamidronate (30 mg every 3 months) and 52 matched controls treated with standard therapy, all with osteoporosis." | 7.73 | Comparison of intravenous pamidronate to standard therapy for osteoporosis: use in patients unable to take oral bisphosphonates. ( Chretien, KC; Klag, MJ; Levine, MA; Liu, YP; Meoni, LA; Miller, RG, 2005) |
| "To examine the response to single-day intravenous pamidronate in a heterogeneous population with symptomatic osteoporosis." | 7.72 | Treatment of symptomatic pediatric osteoporosis with cyclic single-day intravenous pamidronate infusions. ( Steelman, J; Zeitler, P, 2003) |
| "Paired lateral radiographs of the lumbar spine were obtained before and after pamidronate treatment in 5 children with primary osteoporosis." | 7.72 | Effect of pamidronate treatment on vertebral deformity in children with primary osteoporosis. A pilot study using radiographic morphometry. ( Körber, F; Land, C; Rieger-Wettengl, G; Schoenau, E; Stabrey, A; Sumník, Z, 2004) |
| "The aim of this study was to evaluate the efficacy of intravenous pamidronate in patients with transient osteoporosis of the hip (TOH)." | 7.71 | Intravenous pamidronate in the treatment of transient osteoporosis of the hip. ( Binelli, L; Failoni, S; Gallazzi, M; Sinigaglia, L; Varenna, M; Zucchi, F, 2002) |
| " pamidronate in patients with osteoporosis." | 7.71 | A pharmacokinetic and pharmacodynamic model for intravenous bisphosphonate (pamidronate) in osteoporosis. ( Cremers, S; den, HJ; Hamdy, N; Papapoulos, S; Sparidans, R; Vermeij, P, 2002) |
| "To investigate the use of the aminobisphosphonate, disodium pamidronate, in children with vertebral osteoporosis." | 7.70 | Intravenous pamidronate in juvenile osteoporosis. ( Boivin, CM; Crabtree, NJ; Shaw, NJ, 2000) |
| "Pamidronate, a bisphosphonate analogue has been evaluated in a retrospective study for its analgesic effect on chronic back pain due to vertebral fractures in 26 patients suffering from senile osteoporosis or glucocorticoid-induced osteoporosis." | 7.70 | Analgesic effect of intravenous pamidronate on chronic back pain due to osteoporotic vertebral fractures. ( Appelboom, T; Gangji, V, 1999) |
| "We have previously reported that long-term uninterrupted treatment of patients with osteoporosis with oral pamidronate is associated with increases in bone mineral content (BMC) of the lumbar spine which could not be explained by the antiresorptive action of the drug alone, raising the possibility of an additional effect of the treatment on skeletal tissue." | 7.69 | Uninterrupted oral bisphosphonate (pamidronate) therapy of patients with osteoporosis is not associated with chronic stimulation of parathyroid hormone secretion. ( Landman, JO; Papapoulos, SE, 1995) |
| "Seventeen patients (five male) with chronic corticosteroid dependent lung disease (15 asthma, two sarcoidosis) were treated with infusions of 30 mg pamidronate once every three months for one year." | 7.68 | Intravenous pamidronate in the treatment of osteoporosis associated with corticosteroid dependent lung disease: an open pilot study. ( Anderson, K; Banham, SW; Boyle, IT; Bryden, FM; Cowan, RA; Fenner, JA; Gallacher, SJ; Logue, FC, 1992) |
| "Pamidronate treatment stimulated the onset of recovery phase reducing fracture rate and permanent disabilities without evidence of side-effects." | 6.78 | Pamidronate treatment stimulates the onset of recovery phase reducing fracture rate and skeletal deformities in patients with idiopathic juvenile osteoporosis: comparison with untreated patients. ( Baroncelli, GI; Bertelloni, S; Erba, P; Giuca, MR; Vierucci, F; Zampollo, E, 2013) |
| "All patients had osteopenia, diminished osteoid formation and bone volume on histomorphometry pre-therapy with high turnover bone disease (HTO) in TM and low-turnover disease (LTO) in TI." | 6.77 | Prospective study of histomorphometry, biochemical bone markers and bone densitometric response to pamidronate in β-thalassaemia presenting with osteopenia-osteoporosis syndrome. ( Bajoria, R; Byers, M; Chatterjee, R; Davis, BA; Porter, JB; Pringle, J; Shah, FT; Sooranna, D, 2012) |
| "Pamidronate 30 mg was given intravenously every 3 months after LT for the duration of 1 year to 43 patients with osteopenia or osteoporosis prior LT." | 6.73 | Pamidronate and osteoporosis prevention in liver transplant recipients. ( Fiore, CE; Giostra, E; Mentha, G; Pennisi, P; Rizzoli, R; Trombetti, A, 2007) |
| "One of the most common complications in thalassemia major patients is osteopenia and osteoporosis." | 5.43 | Which pamidronate protocol is the best for treating osteoporosis in beta-thalassemia major? ( Kowsaryan, M; Zafari, M, 2016) |
| "Osteoporosis is a major complication of chronic cholestatic liver disease (CCLD)." | 5.38 | Pamidronate for the treatment of osteoporosis secondary to chronic cholestatic liver disease in Wistar rats. ( de Paula, FJ; Defino, HL; Facincani, I; Jorgetti, V; Mattar, R; Pereira, FA; Ramalho, LN; Volpon, JB, 2012) |
| " However, clinical efficacy and optimal dosing in non-OI patients has not been established." | 5.37 | Treatment of symptomatic osteoporosis in children: a comparison of two pamidronate dosage regimens. ( Huang, C; Martinez-Soto, T; Pacaud, D; Stephure, D; Trussell, R, 2011) |
| "Pamidronate 30 mg was administered on 26 osteoporotic patients; and acute phase reactants, inflammatory cytokines and bone biomarkers were measured." | 5.36 | Acute effects of intravenous administration of pamidronate in patients with osteoporosis. ( Kwon, SR; Lim, MJ; Park, SG; Park, W, 2010) |
| "Transient migratory osteoporosis is characterized by the acute onset of migratory pain at weight-bearing joints." | 5.34 | Transient migratory osteoporosis: rapid response to pamidronate treatment. ( Carty, S; Herdman, G; Srinivasan, U; Williams, F, 2007) |
| "Fractures due to osteoporosis are one of the major complications after heart transplantation, occurring mostly during the first 6 months after the graft, with an incidence ranging from 18% to 50% for vertebral fractures." | 5.31 | Intravenous pamidronate as treatment for osteoporosis after heart transplantation: a prospective study. ( Berguer, DG; Burckhardt, P; Goy, JJ; Krieg, MA; Sandini, L; Seydoux, C; Thiébaud, D, 2001) |
| "We discuss this approach of treating osteoporosis with corticoids and immunosuppressors according to the present knowledge of bone biology." | 5.31 | [Vertebral osteoporosis induced by corticoids and cyclosporine ina a patient with Still disease]. ( Fassi, J; Plantalech, L, 2001) |
| "Zoledronic acid is at least as effective as pamidronate as treatment for paediatric osteoporosis, and has a similar safety profile." | 5.14 | Safety and efficacy of intravenous zoledronic acid in paediatric osteoporosis. ( Brown, JJ; Zacharin, MR, 2009) |
| "Our aim was to compare the analgesic efficacy of pamidronate (PAM) and synthetic human calcitonin (CT) in intravenous infusion for recent painful benign vertebral compression in a randomised prospective double-blind study." | 5.12 | Comparison of the analgesic efficacy of pamidronate and synthetic human calcitonin in osteoporotic vertebral fractures: a double-blind controlled study. ( Cantagrel, A; Cantogrel, S; Constantin, A; Jamard, B; Laroche, M; Mazières, B; Zabraniecki, L, 2006) |
| "We performed a randomized, double-blind, controlled clinical trial comparing intravenous pamidronate and placebo for pain relief in recent osteoporotic vertebral compression fractures (VCF)." | 5.12 | Intravenous pamidronate for pain relief in recent osteoporotic vertebral compression fracture: a randomized double-blind controlled study. ( Armingeat, T; Brondino, R; Lafforgue, P; Legré, V; Pham, T, 2006) |
| "We aimed to determine the efficacy and safety of a cyclic intravenous therapy with pamidronate in patients with postmenopausal or glucocorticoid-induced osteoporosis." | 5.11 | Pamidronate increases bone mineral density in women with postmenopausal or steroid-induced osteoporosis. ( Cauza, E; Dunky, A; Etemad, M; Hanusch-Enserer, H; Hanusch-Enserer, U; Noske, H; Partsch, G; Winkler, F, 2004) |
| "5) nonambulatory children with cerebral palsy or a neuromuscular disorder received cyclic intravenous administration of pamidronate." | 5.11 | Cyclic administration of pamidronate to treat osteoporosis in children with cerebral palsy or a neuromuscular disorder: a clinical study. ( Allington, N; Gerard, P; Vivegnis, D, 2005) |
| "The efficacy and safety of oral pamidronate was examined in a double-blind, placebo-controlled trial in women and men with established osteoporosis." | 5.10 | Daily oral pamidronate in women and men with osteoporosis: a 3-year randomized placebo-controlled clinical trial with a 2-year open extension. ( Brumsen, C; Geelhoed-Duijvestijn, PH; Hamdy, NA; Landman, JO; Lips, P; McCloskey, EV; Netelenbos, JC; Papapoulos, SE; Pauwels, EK; Roos, JC; Valentijn, RM; Zwinderman, AH, 2002) |
| "The effect of pamidronate therapy on bone histology was studied in patients with osteoporosis with at least one vertebral fracture in a randomized, double-masked, placebo-controlled, multi-center trial." | 5.09 | Bone histomorphometric evaluation of pamidronate treatment in clinically manifest osteoporosis. ( Bravenboer, N; Hamdy, NA; Holzmann, P; Lips, P; Netelenbos, JC; Papapoulos, SE, 1999) |
| "The effect of oral pamidronate on bone mineral density and its adverse effect profile was investigated by a double-masked placebo-controlled study of 122 patients aged 55-75 years with established vertebral osteoporosis." | 5.09 | Intermittent oral disodium pamidronate in established osteoporosis: a 2 year double-masked placebo-controlled study of efficacy and safety. ( Blake, GM; Davie, M; Fogelman, I; Gibson, T; Haddaway, M; Ryan, PJ, 2000) |
| " Irrespective of the mode of osteoporosis prevention, osteocalcin levels increased whereas urinary deoxypyridinoline decreased after transplantation, and significant bone loss was observed in both treatment groups." | 5.09 | Prevention of osteoporosis in heart transplant recipients: a comparison of calcitriol with calcitonin and pamidronate. ( Bianda, T; Brunner, H; Junga, G; Kiowski, W; Linka, A; Schmid, C; Steinert, H, 2000) |
| "The aim of this study was to compare the action of two regimens of intravenous (iv) pamidronate in the primary prevention of glucocorticoid-induced osteoporosis (GC-OP)." | 5.09 | Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone. ( Boutsen, Y; Devogelaer, JP; Esselinckx, W; Jamart, J, 2001) |
| " administration of disodium pamidronate can effectively achieve primary prevention of glucocorticoid-induced osteoporosis (GIOP)." | 5.08 | Primary prevention of glucocorticoid-induced osteoporosis with intermittent intravenous pamidronate: a randomized trial. ( Boutsen, Y; Devogelaer, JP; Esselinckx, W; Jamart, J; Stoffel, M, 1997) |
| "Pamidronate (aminohydroxypropylidine bisphosphonate, APD) is an effective agent for treatment of Paget's disease of bone, and it has also been thought to be effective for treatment of osteoporosis." | 5.07 | Pamidronate: an unrecognized problem in gastrointestinal tolerability. ( Argueta, R; Cameron, AL; Egan, KS; Lufkin, EG; O'Fallon, WM; Riggs, BL; Whitaker, MD; Wong, VH, 1994) |
| "There is increasing evidence that pamidronate and related compounds are effective in the prevention and treatment of osteoporosis." | 5.06 | Prevention of glucocorticoid-induced osteoporosis. ( Reid, IR; Schooler, BA; Stewart, AW, 1990) |
| "For more than 10 years, based on the results with the bisphosphonate clodronic acid, it has been discussed, whether the occurrence of breast cancer metastases can be avoided or at least delayed by administration of bisphosphonates." | 4.86 | [Bisphosphonates in adjuvant therapy of breast cancer]. ( Deuber, HJ; Theiss, F, 2010) |
| "Of 73 patients, 68 (93%) were treated with pamidronate or zoledronate; 69 (94%) patients suffered from malignant diseases, 3 (5%) had osteoporosis, and 1 (1%) had Paget's disease." | 4.83 | [Bisphosphonate-associated osteonecrosis of the jaw]. ( Abu-Id, MH; Açil, Y; Gottschalk, J; Kreusch, T, 2006) |
| " The parent compound, etidronate, was first used in multicentered trials for the treatment of primary osteoporosis and showed some success in increasing bone density and perhaps controlling fracture rates." | 4.79 | Bisphosphonate therapy. ( Licata, AA, 1997) |
| "The exposure to PEMF40Hz, significantly restored osteoporosis and attenuated bone fragility in comparison to the rats exposed to PEMF25Hz or those treated with pamidronate, vitamin D, and calcium supplementation." | 4.31 | Pulsed electromagnetic field attenuates bone fragility in estrogen-deficient osteoporosis in rats. ( Matavulj, M; Nežić, L; Popović, T; Radulović, TN; Škrbić, R, 2023) |
| "Atypical femur fracture (AFF) is a rare but catastrophic adverse event first reported in the long-term use of alendronate, one of the most commonly used drugs for osteoporosis currently." | 4.31 | Atypical femur fracture associated with common anti-osteoporosis drugs in FDA adverse event reporting system. ( Chen, Y; Huang, Y; Xiao, Y, 2023) |
| "To explore the effects of pamidronate disodium combined with calcium on BMD values and the severity of pain in elderly patients with osteoporosis based on the mobile terminal platform for the Internet of Things." | 4.12 | Effects of Pamidronate Disodium Combined with Calcium on BMD Values and Severity of Pain in Elderly Patients with Osteoporosis Based on Mobile Terminal Platform for Internet of Things. ( Bai, Z; Guo, P; Kang, M; Wang, D; Wang, J, 2022) |
| " We present the case of a 16-year-old girl who developed a subtrochanteric femoral stress fracture following pamidronate treatment for idiopathic juvenile osteoporosis." | 3.85 | A Subtrochanteric Femoral Stress Fracture following Bisphosphonate Treatment in an Adolescent Girl. ( Boyce, AM; Collins, MT; Gafni, RI; Tosi, LL, 2017) |
| " Bisphosphonate-treated women with postmenopausal or glucocorticoid-induced osteoporosis showed adequate and consistent changes of bone markers to subsequently administered intravenous pamidronate." | 3.79 | Long-term treatment of osteoporotic women with bisphosphonates does not impair the response to subsequently administered intravenous pamidronate. ( Hamdy, NA; Papapoulos, SE; Yavropoulou, MP, 2013) |
| " Here, a case of a 9-year-old girl with familial HCS and multiple spinal fractures, who has been effectively treated with pamidronate, is presented." | 3.78 | Two-year cyclic infusion of pamidronate improves bone mass density and eliminates risk of fractures in a girl with osteoporosis due to Hajdu-Cheney syndrome. ( Galli-Tsinopoulou, A; Giannopoulou, EZ; Giza, S; Kyrgios, I; Laliotis, N; Maggana, I, 2012) |
| "The aim of this study was to evaluate a possible role of microcracks in the pathogenesis of bisphosphonate-related osteonecrosis of the jaw (ONJ) and to discuss an etiological model." | 3.76 | Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: a possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings. ( Eufinger, H; Hoefert, S; Schmitz, I; Tannapfel, A, 2010) |
| "To analyze the effects of intravenous pamidronate (APD) on bone remodelling, bone mineral density (BMD), fractures and bone mineral metabolism parameters, and the rate of adverse events, with special attention to renal function, in patients with osteoporosis with intolerance and/or any contraindication to oral bisphosphonates." | 3.76 | Effects of intravenous pamidronate on renal function, bone mineral metabolism and bone mass in patients with severe osteoporosis. ( Gifre, L; Guañabens, N; Hernández, MV; Monegal, A; Muxi, A; Peris, P; Reyes, R, 2010) |
| "Thirty-four children with cerebral palsy and severe osteoporosis were treated for approximately 1 yr with pamidronate (three times per year)." | 3.76 | Risk of corrected QT interval prolongation after pamidronate infusion in children. ( Bougnères, P; Linglart, A; Marchand, I; Rothenbuhler, A, 2010) |
| "It could be posited that pamidronate exerted a positive protective effect on the mother's skeleton with no evidence of adverse effects on pregnancy or on the baby's health to date." | 3.76 | Intravenous bisphosphonate treatment and pregnancy: its effects on mother and infant bone health. ( Mastaglia, SR; Oliveri, B; Watman, NP, 2010) |
| "We report on our experience with 13 cases of jaw osteonecrosis in patients treated with amino-bisphosphonates." | 3.74 | Thirteen cases of jaw osteonecrosis in patients on bisphosphonate therapy. ( Bonneterre, J; Cortet, B; Facon, T; Maes, JM; Magro, L; Penel, G; Vieillard, MH, 2008) |
| "Intravenous pamidronate is frequently used for the treatment of osteoporosis in patients who cannot tolerate oral bisphosphonates." | 3.73 | The effect of intravenous pamidronate versus oral alendronate on bone mineral density in patients with osteoporosis. ( Bultink, IE; Dijkmans, BA; Lems, WF; Vis, M, 2005) |
| "We conducted a retrospective study of 26 patients treated with intermittent, intravenous pamidronate (30 mg every 3 months) and 52 matched controls treated with standard therapy, all with osteoporosis." | 3.73 | Comparison of intravenous pamidronate to standard therapy for osteoporosis: use in patients unable to take oral bisphosphonates. ( Chretien, KC; Klag, MJ; Levine, MA; Liu, YP; Meoni, LA; Miller, RG, 2005) |
| "We conclude that intravenous pamidronate in combination with calcium and vitamin D is a well tolerated strategy for treating Crohn's disease associated osteopenia and osteoporosis." | 3.73 | Intravenous pamidronate in combination with calcium and vitamin D: highly effective in the treatment of low bone mineral density in inflammatory bowel disease. ( Deley, M; Hommes, DW; Stokkers, PC; Van Der Spek, M; Van Deventer, SJ; Verberne, HJ, 2006) |
| "To examine the response to single-day intravenous pamidronate in a heterogeneous population with symptomatic osteoporosis." | 3.72 | Treatment of symptomatic pediatric osteoporosis with cyclic single-day intravenous pamidronate infusions. ( Steelman, J; Zeitler, P, 2003) |
| "Paired lateral radiographs of the lumbar spine were obtained before and after pamidronate treatment in 5 children with primary osteoporosis." | 3.72 | Effect of pamidronate treatment on vertebral deformity in children with primary osteoporosis. A pilot study using radiographic morphometry. ( Körber, F; Land, C; Rieger-Wettengl, G; Schoenau, E; Stabrey, A; Sumník, Z, 2004) |
| "The aim of this study was to evaluate the efficacy of intravenous pamidronate in patients with transient osteoporosis of the hip (TOH)." | 3.71 | Intravenous pamidronate in the treatment of transient osteoporosis of the hip. ( Binelli, L; Failoni, S; Gallazzi, M; Sinigaglia, L; Varenna, M; Zucchi, F, 2002) |
| " pamidronate in patients with osteoporosis." | 3.71 | A pharmacokinetic and pharmacodynamic model for intravenous bisphosphonate (pamidronate) in osteoporosis. ( Cremers, S; den, HJ; Hamdy, N; Papapoulos, S; Sparidans, R; Vermeij, P, 2002) |
| " Bone densitometry is particularly effective for early detection of patients at risk for fracture and is of practical interest since patients with osteoporosis can now be treated with Pamidronate." | 3.71 | [Bone evaluation in ten adults with cutaneous mastocytosis]. ( Armingaud, P; Benhamou, CL; Estève, E; Kerdraon, R; Lespessailles, E; Petavy-Catala, C; Zerkak, D, 2002) |
| "Clodronate, etidronate and pamidronate are bisphosphonates introduced in the treatment of hypercalcaemia and osteoporosis." | 3.70 | Accumulation of bisphosphonates in human artery and their effects on human and rat arterial function in vitro. ( Kalliovalkama, J; Kankaanranta, H; Lähteenmäki, T; Pörsti, I; Salenius, JP; Sisto, T; Wu, X; Ylitalo, P; Ylitalo, R, 1998) |
| "Inhibition of skeletal mineralisation is a well-recognized complication of disodium etidronate therapy that was identified in the earliest studies of its use in osteoporosis and Paget's disease." | 3.70 | Gross vertebral collapse associated with long-term disodium etidronate treatment for pelvic Paget's disease. ( MacGowan, JR; Morris, VH; Pringle, J; Stamp, TC, 2000) |
| "To investigate the use of the aminobisphosphonate, disodium pamidronate, in children with vertebral osteoporosis." | 3.70 | Intravenous pamidronate in juvenile osteoporosis. ( Boivin, CM; Crabtree, NJ; Shaw, NJ, 2000) |
| "Three children (ages 9 to 11 years) with osteoporosis pseudoglioma syndrome who had multiple vertebral collapse were treated over a 2-year period with intermittent intravenous bisphosphonate infusions (pamidronate in 2, clodronate in 1)." | 3.70 | Osteoporosis pseudoglioma syndrome: treatment of spinal osteoporosis with intravenous bisphosphonates. ( Cundy, T; Zacharin, M, 2000) |
| " Pamidronate (Aredia(TM)) is the most widely evaluated bisphosphonate and is recommended for most patients with multiple myeloma or breast cancer with bone metastases." | 3.70 | Optimising treatment of bone metastases by Aredia(TM) and Zometa(TM). ( Coleman, RE, 2000) |
| "Pamidronate, a bisphosphonate analogue has been evaluated in a retrospective study for its analgesic effect on chronic back pain due to vertebral fractures in 26 patients suffering from senile osteoporosis or glucocorticoid-induced osteoporosis." | 3.70 | Analgesic effect of intravenous pamidronate on chronic back pain due to osteoporotic vertebral fractures. ( Appelboom, T; Gangji, V, 1999) |
| "We have previously reported that long-term uninterrupted treatment of patients with osteoporosis with oral pamidronate is associated with increases in bone mineral content (BMC) of the lumbar spine which could not be explained by the antiresorptive action of the drug alone, raising the possibility of an additional effect of the treatment on skeletal tissue." | 3.69 | Uninterrupted oral bisphosphonate (pamidronate) therapy of patients with osteoporosis is not associated with chronic stimulation of parathyroid hormone secretion. ( Landman, JO; Papapoulos, SE, 1995) |
| " One of the earliest agents to be investigated, etidronate, is effective in the management of malignant hypercalcemia and, when used orally and intermittently, results in reduced bone loss in osteoporosis." | 3.69 | Role of bisphosphonates in prevention and treatment of bone metastases from breast cancer. ( Ashley, S; Hanson, J; Kanis, JA; McCloskey, E; Paterson, AH; Powles, TJ, 1995) |
| "Seventeen patients (five male) with chronic corticosteroid dependent lung disease (15 asthma, two sarcoidosis) were treated with infusions of 30 mg pamidronate once every three months for one year." | 3.68 | Intravenous pamidronate in the treatment of osteoporosis associated with corticosteroid dependent lung disease: an open pilot study. ( Anderson, K; Banham, SW; Boyle, IT; Bryden, FM; Cowan, RA; Fenner, JA; Gallacher, SJ; Logue, FC, 1992) |
| "Osteoporosis is a disorder of bone mineralisation occurring in about one third of adults with cystic fibrosis." | 3.01 | Bisphosphonates for osteoporosis in people with cystic fibrosis. ( Chang, AB; Conwell, LS; Jeffery, TC, 2023) |
| "Osteoporosis is characterized by low bone mass and micro-architectural deterioration of bone tissue leading to increased bone fragility." | 3.01 | Treatment for osteoporosis in people with beta-thalassaemia. ( Bhardwaj, A; Sinha, NK; Swe, KMM, 2023) |
| "Pamidronate treatment stimulated the onset of recovery phase reducing fracture rate and permanent disabilities without evidence of side-effects." | 2.78 | Pamidronate treatment stimulates the onset of recovery phase reducing fracture rate and skeletal deformities in patients with idiopathic juvenile osteoporosis: comparison with untreated patients. ( Baroncelli, GI; Bertelloni, S; Erba, P; Giuca, MR; Vierucci, F; Zampollo, E, 2013) |
| "All patients had osteopenia, diminished osteoid formation and bone volume on histomorphometry pre-therapy with high turnover bone disease (HTO) in TM and low-turnover disease (LTO) in TI." | 2.77 | Prospective study of histomorphometry, biochemical bone markers and bone densitometric response to pamidronate in β-thalassaemia presenting with osteopenia-osteoporosis syndrome. ( Bajoria, R; Byers, M; Chatterjee, R; Davis, BA; Porter, JB; Pringle, J; Shah, FT; Sooranna, D, 2012) |
| "Pamidronate 30 mg was given intravenously every 3 months after LT for the duration of 1 year to 43 patients with osteopenia or osteoporosis prior LT." | 2.73 | Pamidronate and osteoporosis prevention in liver transplant recipients. ( Fiore, CE; Giostra, E; Mentha, G; Pennisi, P; Rizzoli, R; Trombetti, A, 2007) |
| "Osteoporosis is a long-term complication of allogeneic stem cell transplantation (SCT)." | 2.72 | Serum osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) concentrations in allogeneic stem cell transplant-recipients: a role in bone loss? ( Kananen, K; Laitinen, K; Ruutu, T; Välimäki, MJ; Volin, L, 2006) |
| "Pamidronate treatment was associated with an increase in bone mineral density and may be an effective treatment modality for the management of osteoporosis in children with Menkes disease." | 2.70 | Pamidronate treatment improves bone mineral density in children with Menkes disease. ( Boneh, A; Kanumakala, S; Zacharin, M, 2002) |
| "Pamidronate therapy was associated with suppression of all biochemical markers of bone turnover compared with placebo (repeated measures ANOVA; p < 0." | 2.70 | Effect of pamidronate in preventing local bone loss after total hip arthroplasty: a randomized, double-blind, controlled trial. ( Barrington, NA; Eastell, R; Elson, RA; Hamer, AJ; Peel, NF; Stockley, I; Wilkinson, JM, 2001) |
| "Treatment with pamidronate resulted in a 7." | 2.70 | The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study. ( Bryant, C; De Souza, P; Diamond, TH; Kersley, JH; Lynch, WJ; Smith, A; Winters, J, 2001) |
| "Osteoporosis is a common and serious complication of solid organ transplantation." | 2.70 | Effects of a single infusion of pamidronate prior to liver transplantation: a bone histomorphometric study. ( Alexander, GJ; Compston, JE; Garrahan, NJ; Ninkovic, M; Vedi, S, 2002) |
| "Bone metastases are associated with pathologic fractures, spinal cord compression, and bone pain and can require narcotics or palliative radiation for pain relief." | 2.48 | Bone-targeted agents: preventing skeletal complications in prostate cancer. ( Morgans, AK; Smith, MR, 2012) |
| "Zoledronic acid (4 mg) has been compared to placebo in a randomized Phase III trial involving 422 men with hormone-refractory prostate cancer metastatic to bone." | 2.41 | The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate. ( Gleason, D; Gordon, D; Kowalski, MO; Lipton, A; Reitsma, D; Rosen, L; Saad, F; Seaman, J; Small, E; Smith, M, 2002) |
| "Many of the bisphosphonates inhibit bone resorption, the newest compounds being 10,000 times more active than etidronate, the first bisphosphonate described." | 2.40 | Bisphosphonates: preclinical aspects and use in osteoporosis. ( Fleisch, HA, 1997) |
| "Although osteoporosis is generally regarded as a disease of women, up to 30% of hip fractures and 20% of vertebral fractures occur in men." | 2.40 | Management of male osteoporosis: report of the UK Consensus Group. ( Boyle, IT; Compston, J; Cooper, C; Eastell, R; Fogelman, I; Francis, RM; Hosking, DJ; Purdie, DW; Ralston, S; Reeve, J; Reid, DM; Russell, RG; Stevenson, JC, 1998) |
| "Regional migratory osteoporosis is a rare, but probably underdiagnosed condition with an unclear etiology." | 1.48 | A case of regional migratory osteoporosis. ( Bours, S; Peeters, HRM; Spierings, J, 2018) |
| "Idiopathic juvenile osteoporosis is a primary osteoporosis of unknown aetiology present in previously well children and is a diagnosis of exclusion." | 1.46 | Primary osteoporosis in children. ( Lim, SY; Tan, LO; Vasanwala, RF, 2017) |
| "One of the most common complications in thalassemia major patients is osteopenia and osteoporosis." | 1.43 | Which pamidronate protocol is the best for treating osteoporosis in beta-thalassemia major? ( Kowsaryan, M; Zafari, M, 2016) |
| "Subsequent radiographs revealed a 14-cm abdominal aortic aneurysm eroding the vertebrae." | 1.39 | An unusual cause of spinal bone loss detected by DXA scanning. ( Davie, MW; Davies, H, 2013) |
| " Adverse events were measured by collecting calcium levels before and after infusions." | 1.38 | Evaluation and comparison of safety, convenience and cost of administering intravenous pamidronate infusions to children in the home and ambulatory care settings. ( DeHaai, K; Kreikemeier, RM; Lutz, RE; Rush, ET, 2012) |
| "Osteoporosis is a major complication of chronic cholestatic liver disease (CCLD)." | 1.38 | Pamidronate for the treatment of osteoporosis secondary to chronic cholestatic liver disease in Wistar rats. ( de Paula, FJ; Defino, HL; Facincani, I; Jorgetti, V; Mattar, R; Pereira, FA; Ramalho, LN; Volpon, JB, 2012) |
| " However, clinical efficacy and optimal dosing in non-OI patients has not been established." | 1.37 | Treatment of symptomatic osteoporosis in children: a comparison of two pamidronate dosage regimens. ( Huang, C; Martinez-Soto, T; Pacaud, D; Stephure, D; Trussell, R, 2011) |
| "Osteoporosis is a common complication in children with motor impairments." | 1.37 | Tolerance and effectiveness on pain control of Pamidronate® intravenous infusions in children with neuromuscular disorders. ( Berard, C; Poirot, I; Vuillerot, C; Wagner, S, 2011) |
| "SREs included radiation (79%), pathologic fractures (12%), and hypercalcemia (9%)." | 1.36 | Skeletal-related events (SREs) in breast cancer patients with bone metastases treated in the nontrial setting. ( Clemons, M; Dranatisaris, G; Myers, J; Simmons, C; Trinkaus, M, 2010) |
| "Pamidronate 30 mg was administered on 26 osteoporotic patients; and acute phase reactants, inflammatory cytokines and bone biomarkers were measured." | 1.36 | Acute effects of intravenous administration of pamidronate in patients with osteoporosis. ( Kwon, SR; Lim, MJ; Park, SG; Park, W, 2010) |
| "Osteogenesis imperfecta is characterised by bone fragility leading to fracture and bone deformity, chronic bone pain and reduced mobility." | 1.36 | Characterising and treating osteogenesis imperfecta. ( Bishop, N, 2010) |
| "Transient osteoporosis is a rare condition causing regional pain, immobility and functional compromise." | 1.36 | Transient osteoporosis associated with pregnancy: use of bisphosphonate in treating a lactating mother. ( Jawad, AS; Shaikh, MF; Shenker, NG, 2010) |
| "Osteoporosis is a common complication in thalassemia major (TM)." | 1.35 | Long-term effects of pamidronate in thalassemic patients with severe bone mineral density deficits. ( Cheng, FW; Chu, Y; Lee, V; Leung, TF; Leung, WK; Li, CK; Shing, MM, 2009) |
| "Transient migratory osteoporosis is characterized by the acute onset of migratory pain at weight-bearing joints." | 1.34 | Transient migratory osteoporosis: rapid response to pamidronate treatment. ( Carty, S; Herdman, G; Srinivasan, U; Williams, F, 2007) |
| " However, complications associated with long-term administration of bisphosphonates, such as nonunion after pelvic insufficiency fracture or osteonecrosis of the jaw, have been recently reported in the literature." | 1.34 | High concentrations of pamidronate in bone weaken the mechanical properties of intact femora in a rat model. ( Choo, KS; Kim, JS; Ryu, JH; Won, JH; Yang, KH; Yoon, HK, 2007) |
| "Pamidronate (0." | 1.33 | Pamidronate prevents bone loss and decreased bone strength in adult female and male rats fed an isocaloric low-protein diet. ( Ammann, P; Mekraldi, S; Rizzoli, R; Toromanoff, A, 2005) |
| "Sixty-two (52." | 1.33 | Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. ( Broumand, V; Fortin, M; Marx, RE; Sawatari, Y, 2005) |
| "Here we report 29 cases of bone necrosis of the jaws in patients treated with pamidronate (Aredia), zoledronate (Zometa) and alendronate: 15 underwent surgical procedures and 14 occurred spontaneously." | 1.33 | Bone necrosis of the jaws associated with bisphosphonate treatment: a report of twenty-nine cases. ( Bonaninil, M; Corcione, L; Corradi, D; D'Aleo, P; Ferrari, S; Guidotti, R; Manfredi, M; Meleti, M; Merigo, E; Poli, T; Ripasarti, A; Sesenna, E; Vescovi, P; Zanzucchi, E, 2006) |
| "Pretreatment with ibuprofen or acetaminophen appears to decrease the occurrence of adverse events from pamidronate therapy." | 1.32 | Effectiveness of pretreatment in decreasing adverse events associated with pamidronate in children and adolescents. ( Bates, CM; Batisky, DL; Hayes, JR; Mahan, JD; Nahata, MC; Robinson, RE, 2004) |
| "Osteoporosis is known to be associated with Crohn's disease." | 1.31 | Osteoporosis: an unusual presentation of childhood Crohn's disease. ( Berdon, W; Bilezikian, JP; Gertner, JM; Harbison, M; Horlick, M; Levine, LS; Levy, J; Oberfield, SE; Thearle, M, 2000) |
| "Fractures due to osteoporosis are one of the major complications after heart transplantation, occurring mostly during the first 6 months after the graft, with an incidence ranging from 18% to 50% for vertebral fractures." | 1.31 | Intravenous pamidronate as treatment for osteoporosis after heart transplantation: a prospective study. ( Berguer, DG; Burckhardt, P; Goy, JJ; Krieg, MA; Sandini, L; Seydoux, C; Thiébaud, D, 2001) |
| "We discuss this approach of treating osteoporosis with corticoids and immunosuppressors according to the present knowledge of bone biology." | 1.31 | [Vertebral osteoporosis induced by corticoids and cyclosporine ina a patient with Still disease]. ( Fassi, J; Plantalech, L, 2001) |
| "Osteoporosis is common in patients with chronic cholestatic liver disease, and atraumatic spinal fracture is a recognized complication after orthotopic liver transplantation." | 1.30 | Intravenous bisphosphonate prevents symptomatic osteoporotic vertebral collapse in patients after liver transplantation. ( Day, CP; Francis, RM; Hudson, M; Manas, DM; Reeves, HL, 1998) |
| "With respect to markers of bone resorption, urinary deoxypyridinoline fell by 51% +/- 9% in group A patients and increased by 65% +/- 22% in group B patients by 3 months after transplantation (P < ." | 1.30 | Prevention of bone loss after heart transplantation with antiresorptive therapy: a pilot study. ( Addesso, V; Lo, SH; Mancini, D; McMahon, DJ; Michler, RE; Rodino, MA; Seibel, MJ; Shane, E; Staron, RB, 1998) |
| "Thus, the increased bone resorption, which is a consequence of estrogen-deficiency, entrains increased bone formation, which masks a simultaneous reduction in estrogen-dependent bone formation." | 1.28 | Estrogen maintains trabecular bone volume in rats not only by suppression of bone resorption but also by stimulation of bone formation. ( Chambers, TJ; Chow, J; Colston, KW; Tobias, JH, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (4.92) | 18.7374 |
| 1990's | 32 (17.49) | 18.2507 |
| 2000's | 92 (50.27) | 29.6817 |
| 2010's | 45 (24.59) | 24.3611 |
| 2020's | 5 (2.73) | 2.80 |
| Authors | Studies |
|---|---|
| Bai, Z | 1 |
| Wang, J | 1 |
| Kang, M | 1 |
| Guo, P | 1 |
| Wang, D | 1 |
| Jeffery, TC | 1 |
| Chang, AB | 1 |
| Conwell, LS | 1 |
| Popović, T | 1 |
| Matavulj, M | 1 |
| Nežić, L | 1 |
| Radulović, TN | 1 |
| Škrbić, R | 1 |
| Bhardwaj, A | 1 |
| Swe, KMM | 1 |
| Sinha, NK | 1 |
| Xiao, Y | 2 |
| Chen, Y | 1 |
| Huang, Y | 1 |
| Tan, LO | 1 |
| Lim, SY | 1 |
| Vasanwala, RF | 1 |
| Saraff, V | 1 |
| Sahota, J | 1 |
| Crabtree, N | 1 |
| Sakka, S | 1 |
| Shaw, NJ | 3 |
| Högler, W | 1 |
| Spierings, J | 1 |
| Bours, S | 1 |
| Peeters, HRM | 1 |
| Schryver, E | 1 |
| Klein, GL | 1 |
| Herndon, DN | 1 |
| Suman, OE | 1 |
| Branski, LK | 1 |
| Sousse, LE | 1 |
| Yavropoulou, MP | 1 |
| Hamdy, NA | 6 |
| Papapoulos, SE | 13 |
| Baroncelli, GI | 1 |
| Vierucci, F | 1 |
| Bertelloni, S | 1 |
| Erba, P | 1 |
| Zampollo, E | 1 |
| Giuca, MR | 1 |
| Lotan, M | 1 |
| Reves-Siesel, R | 1 |
| Eliav-Shalev, RS | 1 |
| Merrick, J | 1 |
| Ngan, KK | 1 |
| Bowe, J | 1 |
| Goodger, N | 1 |
| Whyte, MP | 1 |
| Madson, KL | 1 |
| Mumm, S | 1 |
| McAlister, WH | 1 |
| Novack, DV | 1 |
| Blair, JC | 1 |
| Helliwell, TR | 1 |
| Stolina, M | 1 |
| Abernethy, LJ | 1 |
| Shahidi, S | 1 |
| Ashrafi, F | 1 |
| Mohammadi, M | 1 |
| Moeinzadeh, F | 1 |
| Atapour, A | 1 |
| Munns, CF | 1 |
| Fahiminiya, S | 1 |
| Poudel, N | 1 |
| Munteanu, MC | 1 |
| Majewski, J | 1 |
| Sillence, DO | 1 |
| Metcalf, JP | 1 |
| Biggin, A | 1 |
| Glorieux, F | 1 |
| Fassier, F | 1 |
| Rauch, F | 1 |
| Hinsdale, ME | 1 |
| Zyma, AM | 1 |
| Guk, YM | 1 |
| Magomedov, OM | 1 |
| Gayko, OG | 1 |
| Kincha-Polishchuk, TA | 1 |
| Kowsaryan, M | 1 |
| Zafari, M | 1 |
| Veszelyné Kotán, E | 2 |
| Mészaros, Á | 2 |
| Singh, A | 1 |
| Schaeffer, EK | 1 |
| Reilly, CW | 1 |
| Boyce, AM | 2 |
| Collins, MT | 1 |
| Tosi, LL | 1 |
| Gafni, RI | 2 |
| Barros, ER | 1 |
| Dias da Silva, MR | 1 |
| Kunii, IS | 1 |
| Lazaretti-Castro, M | 1 |
| Gangoiti, MV | 1 |
| Cortizo, AM | 1 |
| Arnol, V | 1 |
| Felice, JI | 1 |
| McCarthy, AD | 1 |
| Skordis, N | 1 |
| Ioannou, YS | 1 |
| Kyriakou, A | 1 |
| Savva, SC | 1 |
| Efstathiou, E | 1 |
| Savvides, I | 1 |
| Christou, S | 1 |
| Brown, JJ | 2 |
| Zacharin, MR | 2 |
| Davis, KW | 1 |
| Trinkaus, M | 1 |
| Simmons, C | 1 |
| Myers, J | 1 |
| Dranatisaris, G | 1 |
| Clemons, M | 1 |
| Hoefert, S | 1 |
| Schmitz, I | 1 |
| Tannapfel, A | 1 |
| Eufinger, H | 1 |
| Atas, A | 1 |
| Cakmak, A | 1 |
| Soran, M | 1 |
| Soker, M | 1 |
| Varma, M | 1 |
| Hou, JW | 1 |
| Leung, TF | 1 |
| Chu, Y | 1 |
| Lee, V | 1 |
| Cheng, FW | 1 |
| Leung, WK | 1 |
| Shing, MM | 1 |
| Li, CK | 1 |
| Chatterjee, R | 2 |
| Bajoria, R | 2 |
| Hernández, MV | 1 |
| Peris, P | 1 |
| Monegal, A | 1 |
| Reyes, R | 1 |
| Muxi, A | 1 |
| Gifre, L | 1 |
| Guañabens, N | 1 |
| Treeprasertsuk, S | 1 |
| Silveira, MG | 1 |
| Petz, JL | 1 |
| Lindor, KD | 1 |
| Rothenbuhler, A | 1 |
| Marchand, I | 1 |
| Bougnères, P | 1 |
| Linglart, A | 1 |
| Mastaglia, SR | 1 |
| Watman, NP | 1 |
| Oliveri, B | 1 |
| Lim, MJ | 1 |
| Kwon, SR | 1 |
| Park, SG | 1 |
| Park, W | 1 |
| Bishop, N | 1 |
| Deuber, HJ | 1 |
| Theiss, F | 1 |
| Vujasinovic-Stupar, N | 1 |
| Pejnovic, N | 1 |
| Markovic, L | 1 |
| Zlatanovic, M | 1 |
| Ludwig, H | 1 |
| Zojer, N | 1 |
| Marcuzzi, A | 1 |
| Zanin, V | 1 |
| Vuch, J | 1 |
| Pontillo, A | 1 |
| Crovella, S | 1 |
| Laroche, M | 2 |
| Livideanu, C | 1 |
| Paul, C | 1 |
| Cantagrel, A | 2 |
| Martinez-Soto, T | 1 |
| Pacaud, D | 1 |
| Stephure, D | 1 |
| Trussell, R | 1 |
| Huang, C | 1 |
| Wagner, S | 1 |
| Poirot, I | 1 |
| Vuillerot, C | 1 |
| Berard, C | 1 |
| Bartl, R | 1 |
| Rozenbaum, M | 1 |
| Boulman, N | 1 |
| Rimar, D | 1 |
| Kaly, L | 1 |
| Rosner, I | 1 |
| Slobodin, G | 1 |
| Jacobsen, C | 1 |
| Metzler, P | 1 |
| Rössle, M | 1 |
| Obwegeser, J | 1 |
| Zemann, W | 1 |
| Grätz, KW | 1 |
| Davies, H | 1 |
| Davie, MW | 1 |
| Pastore, S | 1 |
| Londero, M | 1 |
| Barbieri, F | 1 |
| Di Leo, G | 2 |
| Paparazzo, R | 1 |
| Ventura, A | 2 |
| Freiberger, JJ | 1 |
| Padilla-Burgos, R | 1 |
| McGraw, T | 1 |
| Suliman, HB | 1 |
| Kraft, KH | 1 |
| Stolp, BW | 1 |
| Moon, RE | 1 |
| Piantadosi, CA | 1 |
| Galli-Tsinopoulou, A | 1 |
| Kyrgios, I | 1 |
| Giza, S | 1 |
| Giannopoulou, EZ | 1 |
| Maggana, I | 1 |
| Laliotis, N | 1 |
| Shenker, NG | 2 |
| Shaikh, MF | 1 |
| Jawad, AS | 2 |
| Rush, ET | 1 |
| DeHaai, K | 1 |
| Kreikemeier, RM | 1 |
| Lutz, RE | 1 |
| Shah, FT | 1 |
| Davis, BA | 1 |
| Byers, M | 1 |
| Sooranna, D | 1 |
| Pringle, J | 2 |
| Porter, JB | 1 |
| Pereira, FA | 1 |
| Mattar, R | 1 |
| Facincani, I | 1 |
| Defino, HL | 1 |
| Ramalho, LN | 1 |
| Jorgetti, V | 1 |
| Volpon, JB | 1 |
| de Paula, FJ | 1 |
| Morgans, AK | 1 |
| Smith, MR | 2 |
| Varenna, M | 1 |
| Zucchi, F | 1 |
| Binelli, L | 1 |
| Failoni, S | 1 |
| Gallazzi, M | 1 |
| Sinigaglia, L | 1 |
| Tüzün, S | 1 |
| Kanumakala, S | 1 |
| Boneh, A | 1 |
| Zacharin, M | 2 |
| Lipton, A | 1 |
| Small, E | 1 |
| Saad, F | 2 |
| Gleason, D | 1 |
| Gordon, D | 1 |
| Smith, M | 1 |
| Rosen, L | 1 |
| Kowalski, MO | 1 |
| Reitsma, D | 1 |
| Seaman, J | 1 |
| Dodidou, P | 1 |
| Bruckner, T | 1 |
| Hosch, S | 1 |
| Haass, M | 1 |
| Klar, E | 1 |
| Sauer, P | 1 |
| Ziegler, R | 1 |
| Leidig-Bruckner, G | 1 |
| Steelman, J | 1 |
| Zeitler, P | 1 |
| Pappagallo, M | 1 |
| Breuer, B | 1 |
| Schneider, A | 1 |
| Sperber, K | 1 |
| Voskaridou, E | 1 |
| Terpos, E | 1 |
| Spina, G | 1 |
| Palermos, J | 1 |
| Rahemtulla, A | 1 |
| Loutradi, A | 1 |
| Loukopoulos, D | 1 |
| Sumník, Z | 1 |
| Land, C | 1 |
| Rieger-Wettengl, G | 1 |
| Körber, F | 1 |
| Stabrey, A | 1 |
| Schoenau, E | 1 |
| Robinson, RE | 1 |
| Nahata, MC | 1 |
| Hayes, JR | 1 |
| Batisky, DL | 1 |
| Bates, CM | 1 |
| Mahan, JD | 1 |
| Chan, SS | 1 |
| Nery, LM | 1 |
| McElduff, A | 1 |
| Wilmshurst, EG | 1 |
| Fulcher, GR | 1 |
| Robinson, BG | 1 |
| Stiel, JN | 1 |
| Gunton, JE | 1 |
| Clifton-Bligh, PB | 1 |
| Neri, E | 1 |
| Gharib, S | 1 |
| Cauza, E | 1 |
| Etemad, M | 1 |
| Winkler, F | 1 |
| Hanusch-Enserer, U | 1 |
| Hanusch-Enserer, H | 1 |
| Partsch, G | 1 |
| Noske, H | 1 |
| Dunky, A | 1 |
| Allington, N | 1 |
| Vivegnis, D | 1 |
| Gerard, P | 1 |
| Kananen, K | 2 |
| Volin, L | 2 |
| Laitinen, K | 2 |
| Alfthan, H | 1 |
| Ruutu, T | 2 |
| Välimäki, MJ | 2 |
| Vis, M | 1 |
| Bultink, IE | 1 |
| Dijkmans, BA | 1 |
| Lems, WF | 1 |
| Jimenez-Soriano, Y | 1 |
| Bagan, JV | 1 |
| Ebeling, PR | 2 |
| Woo, SB | 1 |
| Hande, K | 1 |
| Richardson, PG | 1 |
| Mekraldi, S | 1 |
| Toromanoff, A | 1 |
| Rizzoli, R | 4 |
| Ammann, P | 2 |
| Nzeusseu Toukap, A | 1 |
| Depresseux, G | 1 |
| Devogelaer, JP | 4 |
| Houssiau, FA | 1 |
| Assous, N | 1 |
| Foltz, V | 1 |
| Fautrel, B | 1 |
| Rozenberg, S | 1 |
| Etchepare, F | 1 |
| Bourgeois, P | 1 |
| Marx, RE | 1 |
| Sawatari, Y | 1 |
| Fortin, M | 1 |
| Broumand, V | 1 |
| Kim, SD | 1 |
| Cho, BS | 1 |
| Miller, RG | 1 |
| Chretien, KC | 1 |
| Meoni, LA | 1 |
| Liu, YP | 1 |
| Klag, MJ | 1 |
| Levine, MA | 1 |
| Cantogrel, S | 1 |
| Jamard, B | 1 |
| Constantin, A | 1 |
| Zabraniecki, L | 1 |
| Mazières, B | 1 |
| Abu-Id, MH | 1 |
| Açil, Y | 1 |
| Gottschalk, J | 1 |
| Kreusch, T | 1 |
| Stokkers, PC | 1 |
| Deley, M | 1 |
| Van Der Spek, M | 1 |
| Verberne, HJ | 1 |
| Van Deventer, SJ | 1 |
| Hommes, DW | 1 |
| Bayram, F | 1 |
| Tanriverdi, F | 1 |
| Kurtoğlu, S | 1 |
| Atabek, ME | 1 |
| Kula, M | 1 |
| Kaynar, L | 1 |
| Keleştimur, F | 1 |
| Grigg, AP | 1 |
| Shuttleworth, P | 1 |
| Reynolds, J | 1 |
| Schwarer, AP | 1 |
| Szer, J | 1 |
| Bradstock, K | 1 |
| Hui, C | 1 |
| Herrmann, R | 1 |
| Armingeat, T | 1 |
| Brondino, R | 1 |
| Pham, T | 1 |
| Legré, V | 1 |
| Lafforgue, P | 1 |
| Lacy, MQ | 2 |
| Dispenzieri, A | 1 |
| Gertz, MA | 1 |
| Greipp, PR | 1 |
| Gollbach, KL | 1 |
| Hayman, SR | 1 |
| Kumar, S | 1 |
| Lust, JA | 1 |
| Rajkumar, SV | 2 |
| Russell, SJ | 1 |
| Witzig, TE | 1 |
| Zeldenrust, SR | 1 |
| Dingli, D | 1 |
| Bergsagel, PL | 1 |
| Fonseca, R | 1 |
| Reeder, CB | 1 |
| Stewart, AK | 1 |
| Roy, V | 1 |
| Dalton, RJ | 1 |
| Carr, AB | 1 |
| Kademani, D | 2 |
| Keller, EE | 1 |
| Viozzi, CF | 1 |
| Kyle, RA | 1 |
| Koka, S | 1 |
| Pennisi, P | 1 |
| Trombetti, A | 2 |
| Giostra, E | 1 |
| Mentha, G | 1 |
| Fiore, CE | 1 |
| Shetty, N | 1 |
| Hamer, AJ | 2 |
| Stockley, I | 2 |
| Eastell, R | 3 |
| Willkinson, JM | 1 |
| Lucarelli, S | 1 |
| Borrelli, O | 1 |
| Paganelli, M | 1 |
| Capocaccia, P | 1 |
| Frediani, T | 1 |
| Ferri, F | 1 |
| Cucchiara, S | 1 |
| Merigo, E | 1 |
| Manfredi, M | 1 |
| Meleti, M | 1 |
| Guidotti, R | 1 |
| Ripasarti, A | 1 |
| Zanzucchi, E | 1 |
| D'Aleo, P | 1 |
| Corradi, D | 1 |
| Corcione, L | 1 |
| Sesenna, E | 1 |
| Ferrari, S | 1 |
| Poli, T | 1 |
| Bonaninil, M | 1 |
| Vescovi, P | 1 |
| Cremers, SC | 1 |
| Carty, S | 1 |
| Herdman, G | 1 |
| Williams, F | 1 |
| Srinivasan, U | 1 |
| Yang, KH | 1 |
| Won, JH | 1 |
| Yoon, HK | 1 |
| Ryu, JH | 1 |
| Choo, KS | 1 |
| Kim, JS | 1 |
| Vieillard, MH | 1 |
| Maes, JM | 1 |
| Penel, G | 1 |
| Facon, T | 1 |
| Magro, L | 1 |
| Bonneterre, J | 1 |
| Cortet, B | 1 |
| Onwuneme, C | 1 |
| Abdalla, K | 1 |
| Cassidy, N | 1 |
| Hensey, O | 1 |
| Ryan, S | 1 |
| Liu, RH | 1 |
| Werth, VP | 1 |
| Young, SD | 1 |
| Nelson, CL | 1 |
| Steinberg, ME | 1 |
| Adami, S | 1 |
| Frijlink, WB | 2 |
| Bijvoet, OL | 4 |
| O'Riordan, JL | 1 |
| Clemens, TL | 1 |
| van Breukelen, FJ | 1 |
| Sleeboom, HP | 1 |
| Mulder, H | 1 |
| van Oosterom, AT | 1 |
| Landman, JO | 4 |
| Lufkin, EG | 1 |
| Argueta, R | 1 |
| Whitaker, MD | 1 |
| Cameron, AL | 1 |
| Wong, VH | 1 |
| Egan, KS | 1 |
| O'Fallon, WM | 1 |
| Riggs, BL | 1 |
| Schweitzer, DH | 1 |
| Frölich, M | 1 |
| Garnero, P | 2 |
| Grimaux, M | 1 |
| Seguin, P | 1 |
| Delmas, PD | 2 |
| Pauwels, EK | 3 |
| Meyer, JM | 1 |
| Bonjour, JP | 1 |
| Paterson, AH | 1 |
| Kanis, JA | 1 |
| Powles, TJ | 1 |
| McCloskey, E | 1 |
| Hanson, J | 1 |
| Ashley, S | 1 |
| Licata, AA | 1 |
| Fleisch, HA | 1 |
| Marshall, A | 1 |
| Kavanagh, RT | 1 |
| Crisp, AJ | 1 |
| Bonde, M | 1 |
| Fledelius, C | 1 |
| Qvist, P | 1 |
| Christiansen, C | 1 |
| Boutsen, Y | 2 |
| Jamart, J | 2 |
| Esselinckx, W | 2 |
| Stoffel, M | 1 |
| Ringe, JD | 1 |
| Nagant de Deuxchaisnes, C | 1 |
| Boyle, IT | 2 |
| Compston, J | 1 |
| Cooper, C | 1 |
| Fogelman, I | 2 |
| Francis, RM | 2 |
| Hosking, DJ | 1 |
| Purdie, DW | 1 |
| Ralston, S | 1 |
| Reeve, J | 1 |
| Reid, DM | 1 |
| Russell, RG | 1 |
| Stevenson, JC | 1 |
| Reeves, HL | 1 |
| Manas, DM | 1 |
| Hudson, M | 1 |
| Day, CP | 1 |
| Brunel, V | 1 |
| Tadrist, Z | 1 |
| Cailleres, S | 1 |
| Allegre, T | 1 |
| Blanc, AP | 1 |
| Ylitalo, R | 1 |
| Kalliovalkama, J | 1 |
| Wu, X | 1 |
| Kankaanranta, H | 1 |
| Salenius, JP | 1 |
| Sisto, T | 1 |
| Lähteenmäki, T | 1 |
| Ylitalo, P | 1 |
| Pörsti, I | 1 |
| Haworth, CS | 1 |
| Selby, PL | 1 |
| Webb, AK | 1 |
| Mawer, EB | 1 |
| Adams, JE | 1 |
| Freemont, TJ | 1 |
| Shane, E | 1 |
| Rodino, MA | 1 |
| McMahon, DJ | 1 |
| Addesso, V | 1 |
| Staron, RB | 1 |
| Seibel, MJ | 1 |
| Mancini, D | 1 |
| Michler, RE | 1 |
| Lo, SH | 1 |
| Stewart, GO | 1 |
| Gutteridge, DH | 1 |
| Price, RI | 1 |
| Ward, L | 1 |
| Retallack, RW | 1 |
| Prince, RL | 1 |
| Stuckey, BG | 1 |
| Kent, GN | 1 |
| Bhagat, CI | 1 |
| Dhaliwal, SS | 1 |
| Sentongo, TA | 1 |
| Haber, B | 1 |
| Bravenboer, N | 1 |
| Holzmann, P | 1 |
| Netelenbos, JC | 2 |
| Lips, P | 2 |
| Guttmann, G | 1 |
| Van Linthoudt, D | 1 |
| Hartman, EE | 1 |
| Daley, J | 1 |
| Ryan, PJ | 1 |
| Blake, GM | 1 |
| Davie, M | 1 |
| Haddaway, M | 1 |
| Gibson, T | 1 |
| Thearle, M | 1 |
| Horlick, M | 1 |
| Bilezikian, JP | 1 |
| Levy, J | 1 |
| Gertner, JM | 1 |
| Levine, LS | 1 |
| Harbison, M | 1 |
| Berdon, W | 1 |
| Oberfield, SE | 1 |
| Abdulla, AJ | 1 |
| MacGowan, JR | 1 |
| Morris, VH | 1 |
| Stamp, TC | 1 |
| Boivin, CM | 1 |
| Crabtree, NJ | 1 |
| Bianda, T | 1 |
| Linka, A | 1 |
| Junga, G | 1 |
| Brunner, H | 1 |
| Steinert, H | 1 |
| Kiowski, W | 1 |
| Schmid, C | 1 |
| Gerbase, MW | 1 |
| Spiliopoulos, A | 1 |
| Slosman, DO | 1 |
| Nicod, LP | 1 |
| Cundy, T | 1 |
| Aris, RM | 1 |
| Lester, GE | 1 |
| Renner, JB | 1 |
| Winders, A | 1 |
| Denene Blackwood, A | 1 |
| Lark, RK | 1 |
| Ontjes, DA | 1 |
| Nierman, DM | 1 |
| Mechanick, JI | 1 |
| Coleman, RE | 1 |
| Lin, CL | 1 |
| Moniz, C | 1 |
| Chow, JW | 1 |
| Moran, EL | 1 |
| Fornasier, TL | 1 |
| Bogoch, TR | 1 |
| Gangji, V | 1 |
| Appelboom, T | 1 |
| Wilkinson, JM | 1 |
| Peel, NF | 1 |
| Elson, RA | 1 |
| Barrington, NA | 1 |
| Krieg, MA | 1 |
| Seydoux, C | 1 |
| Sandini, L | 1 |
| Goy, JJ | 1 |
| Berguer, DG | 1 |
| Thiébaud, D | 1 |
| Burckhardt, P | 1 |
| Fassi, J | 1 |
| Plantalech, L | 1 |
| Das, H | 1 |
| Wang, L | 1 |
| Kamath, A | 1 |
| Bukowski, JF | 1 |
| McGovern, FJ | 1 |
| Zietman, AL | 1 |
| Fallon, MA | 1 |
| Hayden, DL | 1 |
| Schoenfeld, DA | 1 |
| Kantoff, PW | 1 |
| Finkelstein, JS | 1 |
| Dawson-Hughes, B | 1 |
| Cahill, BC | 1 |
| O'Rourke, MK | 1 |
| Parker, S | 1 |
| Stringham, JC | 1 |
| Karwande, SV | 1 |
| Knecht, TP | 1 |
| Little, DG | 2 |
| Cornell, MS | 2 |
| Briody, J | 2 |
| Cowell, CT | 2 |
| Arbuckle, S | 1 |
| Cooke-Yarborough, CM | 1 |
| Diamond, TH | 1 |
| Winters, J | 1 |
| Smith, A | 1 |
| De Souza, P | 1 |
| Kersley, JH | 1 |
| Lynch, WJ | 1 |
| Bryant, C | 1 |
| Geusens, P | 1 |
| Menten, J | 1 |
| Vosse, D | 1 |
| Vanhoof, J | 1 |
| van der Linden, S | 1 |
| Hile, MS | 1 |
| Bilston, L | 1 |
| Brumsen, C | 2 |
| Cremers, S | 1 |
| Sparidans, R | 1 |
| den, HJ | 1 |
| Hamdy, N | 1 |
| Vermeij, P | 1 |
| Papapoulos, S | 2 |
| Armingaud, P | 1 |
| Zerkak, D | 1 |
| Lespessailles, E | 1 |
| Petavy-Catala, C | 1 |
| Kerdraon, R | 1 |
| Benhamou, CL | 1 |
| Estève, E | 1 |
| Geelhoed-Duijvestijn, PH | 1 |
| McCloskey, EV | 1 |
| Roos, JC | 1 |
| Valentijn, RM | 1 |
| Zwinderman, AH | 1 |
| Vedi, S | 1 |
| Ninkovic, M | 2 |
| Garrahan, NJ | 1 |
| Alexander, GJ | 2 |
| Compston, JE | 2 |
| Love, S | 1 |
| Tom, BD | 1 |
| Bearcroft, PW | 1 |
| Gallacher, SJ | 1 |
| Fenner, JA | 1 |
| Anderson, K | 1 |
| Bryden, FM | 1 |
| Banham, SW | 1 |
| Logue, FC | 1 |
| Cowan, RA | 1 |
| Chow, J | 1 |
| Tobias, JH | 1 |
| Colston, KW | 1 |
| Chambers, TJ | 1 |
| Mallmin, H | 1 |
| Ljunghall, S | 1 |
| Larsson, K | 1 |
| Lindh, E | 1 |
| Lockefeer, JH | 1 |
| Reid, IR | 3 |
| Schooler, BA | 1 |
| Stewart, AW | 1 |
| King, AR | 2 |
| Alexander, CJ | 1 |
| Ibbertson, HK | 2 |
| Heap, SW | 1 |
| Valkema, R | 1 |
| Vismans, FJ | 1 |
| Fleisch, H | 1 |
| Anderson, DC | 1 |
| O'Driscoll, JB | 1 |
| Buckler, HM | 1 |
| Cantrill, J | 1 |
| Brown, JD | 1 |
| Hoekman, K | 1 |
| Peters, AC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Denosumab Versus Zoledronic Acid for Patients With Beta-Thalassemia Major-Induced Osteoporosis[NCT03040765] | Phase 3 | 17 participants (Actual) | Interventional | 2018-05-14 | Terminated (stopped due to failed to recruit eligible subjects) | ||
| A Phase I Pilot Trial to Study the Safety and Efficacy of Concomitant Radiotherapy and Zoledronic Acid for the Palliation of Bone Metastases From Breast Cancer, Prostate Cancer and Lung Cancer[NCT00264420] | Phase 1 | 4 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| Prevention of Bone Loss After Pediatric Hematopoietic Cell Transplantation[NCT02074631] | Phase 2 | 80 participants (Actual) | Interventional | 2015-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
17 reviews available for pamidronate and Age-Related Osteoporosis
| Article | Year |
|---|---|
Bisphosphonates for osteoporosis in people with cystic fibrosis.
Topics: Adult; Alendronate; Bone Density Conservation Agents; Child; Cystic Fibrosis; Diphosphonates; Female | 2023 |
Treatment for osteoporosis in people with beta-thalassaemia.
Topics: Adult; Alendronate; beta-Thalassemia; Child; Clodronic Acid; Denosumab; Diphosphonates; Female; Frac | 2023 |
Bone metabolism in pediatric burned patients: A review.
Topics: Adaptor Proteins, Signal Transducing; Aluminum; Body Composition; Bone and Bones; Bone Density; Bone | 2018 |
The risk of bisphosphonate-related osteonecrosis of the jaw in children. A case report and literature review.
Topics: Administration, Intravenous; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conser | 2013 |
[Therapeutic practice of bisphosphonate use and related pharmaceutical issues I].
Topics: Alendronate; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Neoplasms; Clodronic A | 2016 |
[Bisphosphonates in adjuvant therapy of breast cancer].
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Controlled Clini | 2010 |
Supportive therapy in multiple myeloma.
Topics: Anemia; Blood Transfusion; Bone Diseases; Calcitonin; Clodronic Acid; Diphosphonates; Erythropoietin | 2011 |
Bone-targeted agents: preventing skeletal complications in prostate cancer.
Topics: Androgen Antagonists; Antibodies, Monoclonal, Humanized; Bone Density; Bone Neoplasms; Clinical Tria | 2012 |
The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate.
Topics: Adenocarcinoma; Biomarkers; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Diphosphonat | 2002 |
[Bisphosphonate-associated osteonecrosis of the jaw].
Topics: Aged; Bone Density Conservation Agents; Clinical Trials as Topic; Diphosphonates; Female; Humans; Im | 2006 |
Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma.
Topics: Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Minnesota; Multiple Myeloma; O | 2006 |
Bisphosphonate therapy.
Topics: Alendronate; Animals; Bone Density; Bone Resorption; Clodronic Acid; Diphosphonates; Etidronic Acid; | 1997 |
Bisphosphonates: preclinical aspects and use in osteoporosis.
Topics: Alendronate; Animals; Bone Resorption; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Osteo | 1997 |
Management of male osteoporosis: report of the UK Consensus Group.
Topics: Adult; Aged; Aged, 80 and over; Alcoholism; Diphosphonates; Etidronic Acid; Glucocorticoids; Humans; | 1998 |
Bisphosphonates in the treatment of osteoporosis. Principles and efficacy.
Topics: Administration, Oral; Alendronate; Animals; Bone and Bones; Bone Density; Calcium Channel Blockers; | 2000 |
[Diphosphonates in the treatment of osteoporosis].
Topics: Aged; Diphosphonates; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis; Osteoporosis, Postm | 1991 |
[Biphosphonate as a therapeutic drug--experimental studies and clinical application].
Topics: Animals; Calcinosis; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Hypercalcemia; Hyperpar | 1985 |
44 trials available for pamidronate and Age-Related Osteoporosis
| Article | Year |
|---|---|
Pamidronate treatment stimulates the onset of recovery phase reducing fracture rate and skeletal deformities in patients with idiopathic juvenile osteoporosis: comparison with untreated patients.
Topics: Bone Density; Bone Density Conservation Agents; Child; Diphosphonates; Female; Fractures, Bone; Huma | 2013 |
Low-dose pamidronate for treatment of early bone loss following kidney transplantation: a randomized controlled trial.
Topics: Adult; Bone Density; Bone Density Conservation Agents; Calcium; Dietary Supplements; Diphosphonates; | 2015 |
Effect of bisphosphonate treatment on bone mineral density in patients with thalassaemia major.
Topics: Absorptiometry, Photon; Adult; Alendronate; beta-Thalassemia; Bone Density; Bone Density Conservatio | 2008 |
Safety and efficacy of intravenous zoledronic acid in paediatric osteoporosis.
Topics: Adolescent; Bone Density; Bone Density Conservation Agents; Child; Child Development; Child, Prescho | 2009 |
Osteopenia-osteoporosis syndrome in patients with thalassemia: understanding of type of bone disease and response to treatment.
Topics: Absorptiometry, Photon; Anti-Inflammatory Agents; Bone Diseases, Metabolic; Diphosphonates; Female; | 2009 |
Treatment with pamidronate for osteoporosis complicating long-term intestinal failure.
Topics: Absorptiometry, Photon; Adolescent; Bone Density; Bone Density Conservation Agents; Child; Child, Pr | 2012 |
What is the role of hyperbaric oxygen in the management of bisphosphonate-related osteonecrosis of the jaw: a randomized controlled trial of hyperbaric oxygen as an adjunct to surgery and antibiotics.
Topics: Aged; Alendronate; Anti-Bacterial Agents; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone D | 2012 |
Prospective study of histomorphometry, biochemical bone markers and bone densitometric response to pamidronate in β-thalassaemia presenting with osteopenia-osteoporosis syndrome.
Topics: Adolescent; Adult; beta-Thalassemia; Biomarkers; Bone and Bones; Bone Density; Bone Diseases, Metabo | 2012 |
Pamidronate treatment improves bone mineral density in children with Menkes disease.
Topics: Adolescent; Bone Density; Calcium; Child, Preschool; Diphosphonates; Humans; Infusions, Intravenous; | 2002 |
Better late than never? Experience with intravenous pamidronate treatment in patients with low bone mass or fractures following cardiac or liver transplantation.
Topics: Adult; Bone Density; Diphosphonates; Drug Administration Schedule; Female; Femur Neck; Follow-Up Stu | 2003 |
Pamidronate increases bone mineral density in women with postmenopausal or steroid-induced osteoporosis.
Topics: Aged; Anti-Inflammatory Agents; Bone Density; Diphosphonates; Drug Administration Schedule; Female; | 2004 |
Cyclic administration of pamidronate to treat osteoporosis in children with cerebral palsy or a neuromuscular disorder: a clinical study.
Topics: Adolescent; Anti-Inflammatory Agents; Cerebral Palsy; Child; Child, Preschool; Diphosphonates; Drug | 2005 |
Prevention of bone loss after allogeneic stem cell transplantation by calcium, vitamin D, and sex hormone replacement with or without pamidronate.
Topics: Adult; Aged; Bone Density; Bone Remodeling; Calcium Carbonate; Diphosphonates; Female; Gonadal Stero | 2005 |
Oral pamidronate prevents high-dose glucocorticoid-induced lumbar spine bone loss in premenopausal connective tissue disease (mainly lupus) patients.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents; Bone Density; Bone Remodeling; Connective Tis | 2005 |
Pamidronate therapy for preventing steroid-induced osteoporosis in children with nephropathy.
Topics: Bone Density Conservation Agents; Child; Diphosphonates; Female; Glucocorticoids; Humans; Male; Meth | 2006 |
Comparison of the analgesic efficacy of pamidronate and synthetic human calcitonin in osteoporotic vertebral fractures: a double-blind controlled study.
Topics: Aged; Aged, 80 and over; Analgesics; Bone Density Conservation Agents; Calcitonin; Diphosphonates; F | 2006 |
Attempted randomized controlled trial of pamidronate versus calcium and calcitriol supplements for management of steroid-induced osteoporosis in children and adolescents.
Topics: Adolescent; Adult; Bone Density Conservation Agents; Calcitriol; Calcium; Child; Dietary Supplements | 2005 |
Serum osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) concentrations in allogeneic stem cell transplant-recipients: a role in bone loss?
Topics: Absorptiometry, Photon; Adult; Bone Density; Bone Density Conservation Agents; Bone Resorption; Case | 2006 |
Pamidronate reduces bone loss after allogeneic stem cell transplantation.
Topics: Adolescent; Adult; Aged; Bone Density; Bone Remodeling; Cyclosporine; Diphosphonates; Female; Glucoc | 2006 |
Intravenous pamidronate for pain relief in recent osteoporotic vertebral compression fracture: a randomized double-blind controlled study.
Topics: Acute Disease; Aged; Aged, 80 and over; Analgesics; Back Pain; Bone Density Conservation Agents; Dip | 2006 |
Pamidronate and osteoporosis prevention in liver transplant recipients.
Topics: Adult; Aged; Bone Density; Bone Density Conservation Agents; Calcification, Physiologic; Diphosphona | 2007 |
Clinical and radiological outcome of total hip replacement five years after pamidronate therapy. A trial extension.
Topics: Absorptiometry, Photon; Acetabulum; Adult; Aged; Arthroplasty, Replacement, Hip; Bone Density; Bone | 2006 |
Pamidronate: an unrecognized problem in gastrointestinal tolerability.
Topics: Aged; Diphosphonates; Esophagitis; Esophagoscopy; Female; Humans; Middle Aged; Osteoporosis; Pamidro | 1994 |
Recovery of serum calcium concentrations following acute hypocalcemia in patients with osteoporosis on long-term oral therapy with the bisphosphonate pamidronate.
Topics: Acute Disease; Administration, Oral; Aged; Calcium; Diphosphonates; Edetic Acid; Female; Humans; Hyp | 1995 |
Primary prevention of glucocorticoid-induced osteoporosis with intermittent intravenous pamidronate: a randomized trial.
Topics: Absorptiometry, Photon; Adult; Aged; Anti-Inflammatory Agents; Biomarkers; Bone Density; Calcium; Di | 1997 |
Severe bone pain after intravenous pamidronate in adult patients with cystic fibrosis.
Topics: Adult; Anti-Inflammatory Agents; Bone Density; Bone Diseases; Cystic Fibrosis; Diphosphonates; Dose- | 1998 |
Prevention of appendicular bone loss in Paget's disease following treatment with intravenous pamidronate disodium.
Topics: Administration, Oral; Aged; Aged, 80 and over; Bone Density; Calcitriol; Calcium, Dietary; Diphospho | 1999 |
Bone histomorphometric evaluation of pamidronate treatment in clinically manifest osteoporosis.
Topics: Adult; Aged; Anti-Inflammatory Agents; Bone and Bones; Bone Remodeling; Diphosphonates; Double-Blind | 1999 |
Intermittent oral disodium pamidronate in established osteoporosis: a 2 year double-masked placebo-controlled study of efficacy and safety.
Topics: Administration, Oral; Aged; Analysis of Variance; Anti-Inflammatory Agents; Bone Density; Diphosphon | 2000 |
Prevention of osteoporosis in heart transplant recipients: a comparison of calcitriol with calcitonin and pamidronate.
Topics: Absorptiometry, Photon; Administration, Intranasal; Administration, Oral; Adult; Aged; Amino Acids; | 2000 |
Bone mineral density in lung-transplant recipients before and after graft: prevention of lumbar spine post-transplantation-accelerated bone loss by pamidronate.
Topics: Adolescent; Adult; Anti-Inflammatory Agents; Bone Density; Bone Resorption; Calcium; Dietary Supplem | 2000 |
Efficacy of pamidronate for osteoporosis in patients with cystic fibrosis following lung transplantation.
Topics: Adolescent; Adult; Anti-Inflammatory Agents; Bone Density; Cystic Fibrosis; Diphosphonates; Drug Adm | 2000 |
Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone.
Topics: Alkaline Phosphatase; Bone Density; Bone Remodeling; Calcium; Collagen; Collagen Type I; Diphosphona | 2001 |
Effect of pamidronate in preventing local bone loss after total hip arthroplasty: a randomized, double-blind, controlled trial.
Topics: Aged; Alkaline Phosphatase; Amino Acids; Arthroplasty, Replacement, Hip; Biomarkers; Bone Density; B | 2001 |
Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer.
Topics: Aged; Antineoplastic Agents, Hormonal; Bone Density; Bone Resorption; Diphosphonates; Femur; Gonadot | 2001 |
Prevention of bone loss and fracture after lung transplantation: a pilot study.
Topics: Absorptiometry, Photon; Adult; Alendronate; Bone Density; Diphosphonates; Drug Administration Schedu | 2001 |
The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Bone Density; Cr | 2001 |
Daily oral pamidronate in women and men with osteoporosis: a 3-year randomized placebo-controlled clinical trial with a 2-year open extension.
Topics: Administration, Oral; Aged; Bone Density; Diphosphonates; Double-Blind Method; Female; Hip; Humans; | 2002 |
Effects of a single infusion of pamidronate prior to liver transplantation: a bone histomorphometric study.
Topics: Adult; Bone Remodeling; Bone Resorption; Diphosphonates; Female; Humans; Liver Transplantation; Male | 2002 |
Lack of effect of intravenous pamidronate on fracture incidence and bone mineral density after orthotopic liver transplantation.
Topics: Adult; Anti-Inflammatory Agents; Bone Density; Diphosphonates; Female; Humans; Incidence; Injections | 2002 |
Short-term effects of pamidronate on biochemical markers of bone metabolism in osteoporosis--a placebo-controlled dose-finding study.
Topics: Administration, Oral; Aged; Biomarkers; Bone and Bones; Bone Resorption; Diphosphonates; Dose-Respon | 1991 |
Prevention of glucocorticoid-induced osteoporosis.
Topics: Adult; Alkaline Phosphatase; Calcitriol; Clinical Trials as Topic; Diphosphonates; Female; Glucocort | 1990 |
Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD).
Topics: Calcium; Clinical Trials as Topic; Diphosphonates; Female; Glucocorticoids; Humans; Male; Menopause; | 1988 |
Two-year follow-up of biphosphonate (APD) treatment in steroid osteoporosis.
Topics: Diphosphonates; Female; Follow-Up Studies; Glucocorticoids; Humans; Male; Middle Aged; Osteoporosis; | 1988 |
122 other studies available for pamidronate and Age-Related Osteoporosis
| Article | Year |
|---|---|
Effects of Pamidronate Disodium Combined with Calcium on BMD Values and Severity of Pain in Elderly Patients with Osteoporosis Based on Mobile Terminal Platform for Internet of Things.
Topics: Aged; Bone Density; Calcium; Diphosphonates; Humans; Internet of Things; Lumbar Vertebrae; Osteoporo | 2022 |
Pulsed electromagnetic field attenuates bone fragility in estrogen-deficient osteoporosis in rats.
Topics: Animals; Bone Density; Bone Density Conservation Agents; Calcium; Electromagnetic Fields; Estrogens; | 2023 |
Atypical femur fracture associated with common anti-osteoporosis drugs in FDA adverse event reporting system.
Topics: Alendronate; Bone Density Conservation Agents; Denosumab; Diphosphonates; Femur; Humans; Ibandronic | 2023 |
Primary osteoporosis in children.
Topics: Administration, Intravenous; Back Pain; Bone Density Conservation Agents; Child; Diagnosis, Differen | 2017 |
Efficacy and treatment costs of zoledronate versus pamidronate in paediatric osteoporosis.
Topics: Administration, Intravenous; Bone Density; Bone Density Conservation Agents; Child; Diphosphonates; | 2018 |
A case of regional migratory osteoporosis.
Topics: Bone Density Conservation Agents; Diphosphonates; Foot Joints; Hip Joint; Humans; Lower Extremity; M | 2018 |
Long-term treatment of osteoporotic women with bisphosphonates does not impair the response to subsequently administered intravenous pamidronate.
Topics: Administration, Oral; Adult; Aged; Biomarkers; Bone Density; Bone Density Conservation Agents; Colla | 2013 |
Osteoporosis in Rett syndrome: a case study presenting a novel management intervention for severe osteoporosis.
Topics: Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Infant; Osteoporosis | 2013 |
Rapid skeletal turnover in a radiographic mimic of osteopetrosis.
Topics: Bone Remodeling; Child; Diphosphonates; Humans; Male; Osteoporosis; Osteosclerosis; Pamidronate; Rad | 2014 |
Homozygosity for frameshift mutations in XYLT2 result in a spondylo-ocular syndrome with bone fragility, cataracts, and hearing defects.
Topics: Base Sequence; Cataract; Craniofacial Abnormalities; Diphosphonates; Exome; Eye Diseases, Hereditary | 2015 |
[PREPARATIONS OF PAMIDRONOVIC ACID IN COMPLEX TREATMENT ON OSTEOGENESIS IMPERFECTA].
Topics: Bone and Bones; Bone Density; Bone Density Conservation Agents; Calcium; Child; Child, Preschool; Di | 2015 |
Which pamidronate protocol is the best for treating osteoporosis in beta-thalassemia major?
Topics: Adult; beta-Thalassemia; Bone Density; Bone Density Conservation Agents; Diphosphonates; Dose-Respon | 2016 |
[Bisphosphonate use and related pharmaceutical issues II].
Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Bone Neoplasms; Clodronic Acid; | 2016 |
Vertebral Fractures in Duchenne Muscular Dystrophy Patients Managed With Deflazacort.
Topics: Adolescent; Adrenal Cortex Hormones; Bone Density; Bone Density Conservation Agents; Child; Diphosph | 2018 |
A Subtrochanteric Femoral Stress Fracture following Bisphosphonate Treatment in an Adolescent Girl.
Topics: Adolescent; Adult; Child; Diphosphonates; Female; Fractures, Stress; Hip Fractures; Humans; Osteopor | 2017 |
Three years follow-up of pamidronate therapy in two brothers with osteoporosis-pseudoglioma syndrome (OPPG) carrying an LRP5 mutation.
Topics: Antineoplastic Agents; Blindness; Bone Density; Bone Density Conservation Agents; Child; Child, Pres | 2008 |
Opposing effects of bisphosphonates and advanced glycation end-products on osteoblastic cells.
Topics: 3T3 Cells; Alendronate; Animals; Bone Density Conservation Agents; Calcium; Calcium Channels, L-Type | 2008 |
Transient migratory osteoporosis or insufficiency fracture?
Topics: Aged; Aging; Bone Density Conservation Agents; Diagnosis, Differential; Diphosphonates; Female; Frac | 2009 |
Skeletal-related events (SREs) in breast cancer patients with bone metastases treated in the nontrial setting.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Comorbidi | 2010 |
Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: a possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Connective Tissue; Di | 2010 |
Severe osteoporosis and high level TSH in a child before the diagnosis of acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Agents; Bone Density Conservation Agents; Diagnosis, Differential; Diphos | 2009 |
Amelioration of hypophosphatemic rickets and osteoporosis with pamidronate and growth hormone in Lowe syndrome.
Topics: Adolescent; Bone Density; Diphosphonates; Familial Hypophosphatemic Rickets; Genetic Diseases, X-Lin | 2009 |
Long-term effects of pamidronate in thalassemic patients with severe bone mineral density deficits.
Topics: Adolescent; Adult; Blood Transfusion; Bone Density; Bone Density Conservation Agents; Calcium; Dipho | 2009 |
Effects of intravenous pamidronate on renal function, bone mineral metabolism and bone mass in patients with severe osteoporosis.
Topics: Aged; Aged, 80 and over; Bone Density; Diphosphonates; Female; Follow-Up Studies; Humans; Infusions, | 2010 |
Parenteral bisphosphonates for osteoporosis in patients with primary biliary cirrhosis.
Topics: Aged; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Ibandronic Aci | 2011 |
Risk of corrected QT interval prolongation after pamidronate infusion in children.
Topics: Adolescent; Arrhythmias, Cardiac; Cerebral Palsy; Child; Diphosphonates; Electrocardiography; Female | 2010 |
Intravenous bisphosphonate treatment and pregnancy: its effects on mother and infant bone health.
Topics: Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Follow-Up Studies; Gaucher D | 2010 |
Acute effects of intravenous administration of pamidronate in patients with osteoporosis.
Topics: Acute-Phase Proteins; Adult; Aged; Aged, 80 and over; Alendronate; Biomarkers; Blood Cells; Bone Den | 2010 |
Characterising and treating osteogenesis imperfecta.
Topics: Bone and Bones; Bone Density Conservation Agents; Collagen Type I; Diagnosis, Differential; Diphosph | 2010 |
Pregnancy-associated spinal osteoporosis treated with bisphosphonates: long-term follow-up of maternal and infants outcome.
Topics: Adult; Back Pain; Bone Density; Bone Density Conservation Agents; Child; Diphosphonates; Etidronic A | 2012 |
Letter to the editor: acute effects of intravenous administration of pamidronate in patients with osteoporosis.
Topics: Anti-Inflammatory Agents; Cytokines; Diphosphonates; Humans; Injections, Intravenous; Osteoporosis; | 2011 |
Approach to the child with fractures.
Topics: Absorptiometry, Photon; Bone Density; Bone Density Conservation Agents; Child; Diphosphonates; Femal | 2011 |
Interferon alpha and pamidronate in osteoporosis with fracture secondary to mastocytosis.
Topics: Adult; Aged; Bone Density; Bone Density Conservation Agents; Diphosphonates; Drug Therapy, Combinati | 2011 |
Treatment of symptomatic osteoporosis in children: a comparison of two pamidronate dosage regimens.
Topics: Adolescent; Bone Density; Bone Density Conservation Agents; Child; Diphosphonates; Dose-Response Rel | 2011 |
Tolerance and effectiveness on pain control of Pamidronate® intravenous infusions in children with neuromuscular disorders.
Topics: Adolescent; Analgesics; Bone Density Conservation Agents; Child; Diphosphonates; Drug Evaluation; Fe | 2011 |
[Inflammation of the jaws during treatment with bisphosphonates].
Topics: Administration, Oral; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseas | 2011 |
Uncommon transient osteoporosis of pregnancy at multiple sites associated with cytomegalovirus infection: is there a link?
Topics: Absorptiometry, Photon; Adult; Alendronate; Ankle Joint; Bone Density Conservation Agents; Cytomegal | 2011 |
Osteopathology induced by bisphosphonates and dental implants: clinical observations.
Topics: Actinomycosis; Administration, Intravenous; Administration, Oral; Alendronate; Anti-Bacterial Agents | 2013 |
An unusual cause of spinal bone loss detected by DXA scanning.
Topics: Absorptiometry, Photon; Aged; Aortic Aneurysm, Abdominal; Bone Density; Bone Density Conservation Ag | 2013 |
Two-year cyclic infusion of pamidronate improves bone mass density and eliminates risk of fractures in a girl with osteoporosis due to Hajdu-Cheney syndrome.
Topics: Abnormalities, Multiple; Acro-Osteolysis; Bone Density; Bone Density Conservation Agents; Child; Dip | 2012 |
Transient osteoporosis associated with pregnancy: use of bisphosphonate in treating a lactating mother.
Topics: Adult; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Lactation; Osteoporosis; Pa | 2010 |
Evaluation and comparison of safety, convenience and cost of administering intravenous pamidronate infusions to children in the home and ambulatory care settings.
Topics: Adolescent; Ambulatory Care; Bone Density Conservation Agents; Bone Diseases, Metabolic; Child; Cost | 2012 |
Pamidronate for the treatment of osteoporosis secondary to chronic cholestatic liver disease in Wistar rats.
Topics: Animals; Bone Density; Bone Density Conservation Agents; Cholestasis, Intrahepatic; Chronic Disease; | 2012 |
Intravenous pamidronate in the treatment of transient osteoporosis of the hip.
Topics: Adult; Bone Density; Diphosphonates; Female; Hip; Humans; Infusions, Intravenous; Male; Middle Aged; | 2002 |
Pamidronate after heart transplantation.
Topics: Diphosphonates; Heart Transplantation; Humans; Osteoporosis; Pamidronate; Postoperative Period | 2002 |
Treatment of symptomatic pediatric osteoporosis with cyclic single-day intravenous pamidronate infusions.
Topics: Adolescent; Adult; Age Factors; Anti-Inflammatory Agents; Bone Density; Child; Diphosphonates; Drug | 2003 |
Treatment of chronic mechanical spinal pain with intravenous pamidronate: a review of medical records.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Back Pain; Chronic Disease; Diphosphonates | 2003 |
Bisphosphonates in prostate cancer: where are we and where should we go?
Topics: Administration, Oral; Androgen Antagonists; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Bone | 2003 |
Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassaemia.
Topics: Acid Phosphatase; Adult; Alkaline Phosphatase; Anti-Inflammatory Agents; beta-Thalassemia; Biomarker | 2003 |
Effect of pamidronate treatment on vertebral deformity in children with primary osteoporosis. A pilot study using radiographic morphometry.
Topics: Adolescent; Anti-Inflammatory Agents; Child; Child, Preschool; Diphosphonates; Female; Humans; Lumba | 2004 |
Effectiveness of pretreatment in decreasing adverse events associated with pamidronate in children and adolescents.
Topics: Abdominal Pain; Acetaminophen; Adolescent; Child; Child, Preschool; Diphosphonates; Female; Hospital | 2004 |
Intravenous pamidronate in the treatment and prevention of osteoporosis.
Topics: Absorptiometry, Photon; Aged; Bone Density; Diphosphonates; Female; Humans; Infusions, Intravenous; | 2004 |
Using pamidronate for osteoporosis.
Topics: Adolescent; Anti-Inflammatory Agents; Child; Child, Preschool; Diphosphonates; Female; Humans; Male; | 2004 |
By the way, doctor. My wife is 80. In order to increase her bone calcium, she takes calcium citrate tablets. Her doctor now wants to put her on Aredia by IV injection every three months. Since this is not FDA approved, is it a good idea?
Topics: Aged; Aged, 80 and over; Alendronate; Antineoplastic Agents; Calcium Citrate; Diphosphonates; Female | 2004 |
[Rapid drug information].
Topics: Adverse Drug Reaction Reporting Systems; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Drug Info | 2005 |
The effect of intravenous pamidronate versus oral alendronate on bone mineral density in patients with osteoporosis.
Topics: Absorptiometry, Photon; Administration, Oral; Aged; Aged, 80 and over; Alendronate; Anti-Inflammator | 2005 |
Bisphosphonates, as a new cause of drug-induced jaw osteonecrosis: an update.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Infusions, Int | 2005 |
Defective osteoblast function may be responsible for bone loss from the proximal femur despite pamidronate therapy.
Topics: Bone Density; Calcium Carbonate; Diphosphonates; Femur; Gonadal Steroid Hormones; Hematopoietic Stem | 2005 |
Osteonecrosis of the jaw and bisphosphonates.
Topics: Alendronate; Animals; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Osteonecrosis; Osteoporosis; | 2005 |
Pamidronate prevents bone loss and decreased bone strength in adult female and male rats fed an isocaloric low-protein diet.
Topics: Amino Acids; Animals; Biomarkers; Body Weight; Bone and Bones; Bone Density; Diet, Protein-Restricte | 2005 |
Bone involvement in myelofibrosis: effectiveness of bisphosphonates.
Topics: Bone and Bones; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Middle Aged; Osteo | 2005 |
Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment.
Topics: Abscess; Alendronate; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breas | 2005 |
Comparison of intravenous pamidronate to standard therapy for osteoporosis: use in patients unable to take oral bisphosphonates.
Topics: Administration, Oral; Bone Density; Bone Density Conservation Agents; Case-Control Studies; Diphosph | 2005 |
Intravenous pamidronate in combination with calcium and vitamin D: highly effective in the treatment of low bone mineral density in inflammatory bowel disease.
Topics: Absorptiometry, Photon; Adult; Bone Density; Bone Density Conservation Agents; Calcium; Diphosphonat | 2006 |
Effects of 3 years of intravenous pamidronate treatment on bone markers and bone mineral density in a patient with osteoporosis-pseudoglioma syndrome (OPPG).
Topics: Abnormalities, Multiple; Adolescent; Adult; Bone Density; Bone Density Conservation Agents; Central | 2006 |
Primary surgical therapy for osteonecrosis of the jaw secondary to bisphosphonate therapy.
Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazole | 2006 |
Vertebral fractures and increased sensitivity to corticosteroids in a child with ulcerative colitis: successful use of pamidronate.
Topics: Back Pain; Bone Density; Bone Density Conservation Agents; Child; Colitis, Ulcerative; Diphosphonate | 2006 |
Bone necrosis of the jaws associated with bisphosphonate treatment: a report of twenty-nine cases.
Topics: Aged; Aged, 80 and over; Alendronate; Anti-Bacterial Agents; Antifungal Agents; Bone Density Conserv | 2006 |
Prolonged bisphosphonate release after treatment in children.
Topics: Adolescent; Arthritis, Juvenile; Bone Density Conservation Agents; Child; Diphosphonates; Half-Life; | 2007 |
Bisphosphonates and osteonecrosis of the jaw.
Topics: Bone Remodeling; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Neoplasms; Osteonecrosis; Osteopo | 2007 |
Transient migratory osteoporosis: rapid response to pamidronate treatment.
Topics: Adult; Aged; Arthralgia; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Infusions | 2007 |
High concentrations of pamidronate in bone weaken the mechanical properties of intact femora in a rat model.
Topics: Animals; Bone Density Conservation Agents; Diphosphonates; Disease Models, Animal; Female; Femur; Fr | 2007 |
Thirteen cases of jaw osteonecrosis in patients on bisphosphonate therapy.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Jaw; M | 2008 |
Radiological findings in cyclical administration of intravenous pamidronate in children with osteoporosis.
Topics: Adolescent; Bone Density Conservation Agents; Child, Preschool; Diphosphonates; Drug Administration | 2007 |
What is new in the treatment of steroid-induced osteoporosis?
Topics: Bone Density Conservation Agents; Calcitonin; Diphosphonates; Etidronic Acid; Glucocorticoids; Human | 2007 |
Transient osteoporosis of the hip in association with osteogenesis imperfecta: two cases, one complicated by a femoral neck fracture.
Topics: Aged; Anti-Inflammatory Agents; Diphosphonates; Femoral Neck Fractures; Fracture Fixation, Internal; | 2008 |
Non-hormonal treatment of osteoporosis.
Topics: Aged; Calcium, Dietary; Diphosphonates; Female; Humans; Male; Middle Aged; Osteoporosis; Pamidronate | 1983 |
Regulation of calcium absorption by 1,25,dihydroxy-vitamin D--studies of the effects of a bisphosphonate treatment.
Topics: Aged; Bone Resorption; Calcitriol; Calcium; Diphosphonates; Humans; Hypocalcemia; Middle Aged; Ostei | 1982 |
Efficacy of amino-hydroxypropylidene bisphosphonate in hypercalcemia: observations on regulation of serum calcium.
Topics: Adult; Aged; Bone Resorption; Calcium; Diphosphonates; Female; Humans; Hypercalcemia; Hyperparathyro | 1982 |
Uninterrupted oral bisphosphonate (pamidronate) therapy of patients with osteoporosis is not associated with chronic stimulation of parathyroid hormone secretion.
Topics: Administration, Oral; Adult; Aged; Alkaline Phosphatase; Calcium; Diphosphonates; Female; Humans; Hy | 1995 |
Characterization of immunoreactive forms of human osteocalcin generated in vivo and in vitro.
Topics: Adult; Antibodies, Monoclonal; Bone Diseases, Metabolic; Bone Neoplasms; Cell Line; Diphosphonates; | 1994 |
Skeletal metabolism in patients with osteoporosis after discontinuation of long-term treatment with oral pamidronate.
Topics: Administration, Oral; Bone and Bones; Bone Density; Diphosphonates; Female; Femur Neck; Follow-Up St | 1995 |
Bone density and shape as determinants of bone strength in IGF-I and/or pamidronate-treated ovariectomized rats.
Topics: Absorptiometry, Photon; Analysis of Variance; Animals; Bone Density; Compressive Strength; Diphospho | 1996 |
Role of bisphosphonates in prevention and treatment of bone metastases from breast cancer.
Topics: Analgesics, Non-Narcotic; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; D | 1995 |
The effect of pamidronate on lumbar spine bone density and pain in osteoporosis secondary to systemic mastocytosis.
Topics: Adult; Bone Density; Diphosphonates; Female; Humans; Lumbar Vertebrae; Male; Mastocytosis; Middle Ag | 1997 |
Measurement of bone degradation products in serum using antibodies reactive with an isomerized form of an 8 amino acid sequence of the C-telopeptide of type I collagen.
Topics: Adult; Alendronate; Amino Acid Sequence; Antibodies; Biomarkers; Bone Resorption; Collagen; Collagen | 1997 |
[Bisphosphonate therapy in corticoid-induced osteoporosis].
Topics: Adrenal Cortex Hormones; Calcium; Diphosphonates; Drug Therapy, Combination; Estrogens; Etidronic Ac | 1997 |
Use of pamidronate in chronic and acute bone loss conditions.
Topics: Acute Disease; Bone Density; Bone Resorption; Chronic Disease; Diphosphonates; Female; Humans; Male; | 1997 |
Intravenous bisphosphonate prevents symptomatic osteoporotic vertebral collapse in patients after liver transplantation.
Topics: Absorptiometry, Photon; Adult; Aged; Bone Density; Diphosphonates; Female; Follow-Up Studies; Fractu | 1998 |
[Interferon alpha and pamidronate: a useful combination in the treatment of osteoporosis and systemic mastocytosis].
Topics: Anti-Inflammatory Agents; Bone Density; Diphosphonates; Humans; Interferon-alpha; Male; Mastocytosis | 1998 |
Accumulation of bisphosphonates in human artery and their effects on human and rat arterial function in vitro.
Topics: Animals; Arteries; Calcium Channel Blockers; Clodronic Acid; Diphosphonates; Drug Synergism; Etidron | 1998 |
Prevention of bone loss after heart transplantation with antiresorptive therapy: a pilot study.
Topics: Absorptiometry, Photon; Amino Acids; Biomarkers; Bone Density; Bone Resorption; Calcitriol; Calcium; | 1998 |
Progress in the prevention and treatment of osteoporosis in pediatrics.
Topics: Adolescent; Bone Density; Child; Diphosphonates; Humans; Osteoporosis; Pamidronate | 1999 |
[Efficacy of intravenous pamidronate in osteoporosis, mineralometric evaluation].
Topics: Anti-Inflammatory Agents; Diphosphonates; Female; Humans; Male; Middle Aged; Minerals; Osteoporosis; | 1999 |
A 73-year-old woman with osteoporosis, 1 year later.
Topics: Aged; Alendronate; Diphosphonates; Female; Humans; Osteoporosis; Pamidronate | 2000 |
Osteoporosis: an unusual presentation of childhood Crohn's disease.
Topics: Alkaline Phosphatase; Anti-Inflammatory Agents; Child; Crohn Disease; Diphosphonates; Humans; Jews; | 2000 |
Use of pamidronate for acute pain relief following osteoporotic vertebral fractures.
Topics: Acute Disease; Aged; Aged, 80 and over; Analgesics; Diphosphonates; Female; Humans; Middle Aged; Ost | 2000 |
Gross vertebral collapse associated with long-term disodium etidronate treatment for pelvic Paget's disease.
Topics: Aged; Alkaline Phosphatase; Anti-Inflammatory Agents; Arthralgia; Diphosphonates; Etidronic Acid; Fo | 2000 |
Intravenous pamidronate in juvenile osteoporosis.
Topics: Absorptiometry, Photon; Acute-Phase Reaction; Adolescent; Bone Density; Child; Diphosphonates; Femal | 2000 |
Osteoporosis pseudoglioma syndrome: treatment of spinal osteoporosis with intravenous bisphosphonates.
Topics: Analgesics, Non-Narcotic; Bone Density; Child; Clodronic Acid; Diphosphonates; Female; Fractures, Bo | 2000 |
Biochemical response to treatment of bone hyperresorption in chronically critically ill patients.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Biomarkers; Calcitriol; Calcium; Calcium C | 2000 |
Optimising treatment of bone metastases by Aredia(TM) and Zometa(TM).
Topics: Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Hypercalcem | 2000 |
Treatment with fluoride or bisphosphonates prevents bone loss associated with colitis in the rat.
Topics: Animals; Anti-Inflammatory Agents; Colitis; Diphosphonates; Disease Models, Animal; Inflammatory Bow | 2000 |
Pamidronate prevents bone loss associated with carrageenan arthritis by reducing resorptive activity but not recruitment of osteoclasts.
Topics: Animals; Anti-Inflammatory Agents; Arthritis; Bone and Bones; Bone Resorption; Carrageenan; Diphosph | 2000 |
Analgesic effect of intravenous pamidronate on chronic back pain due to osteoporotic vertebral fractures.
Topics: Activities of Daily Living; Aged; Anti-Inflammatory Agents; Back Pain; Diphosphonates; Female; Human | 1999 |
Intravenous pamidronate as treatment for osteoporosis after heart transplantation: a prospective study.
Topics: Bone Density; Cyclosporine; Diphosphonates; Female; Glucocorticoids; Heart Transplantation; Humans; | 2001 |
[Vertebral osteoporosis induced by corticoids and cyclosporine ina a patient with Still disease].
Topics: Adrenal Cortex Hormones; Adult; Benzothiadiazines; Calcitonin; Cyclosporine; Diphosphonates; Diureti | 2001 |
Vgamma2Vdelta2 T-cell receptor-mediated recognition of aminobisphosphonates.
Topics: Alendronate; Antigens; Cell Line, Transformed; Cytotoxicity, Immunologic; Diphosphonates; Etidronic | 2001 |
Bone loss accompanying medical therapies.
Topics: Administration, Inhalation; Antineoplastic Agents, Hormonal; Bone Density; Bone Resorption; Diphosph | 2001 |
Intravenous pamidronate reduces osteoporosis and improves formation of the regenerate during distraction osteogenesis. A study in immature rabbits.
Topics: Animals; Bone Density; Bone Regeneration; Diphosphonates; Infusions, Intravenous; Male; Osteogenesis | 2001 |
Recovery from severe glucocorticoid-induced osteoporosis in an adolescent boy.
Topics: Adolescent; Anti-Inflammatory Agents; Body Height; Bone Density; Brain Stem Neoplasms; Diphosphonate | 2001 |
Effect of pamidronate on distraction osteogenesis and fixator-related osteoporosis.
Topics: Animals; Bone Density; Diphosphonates; Elasticity; External Fixators; Male; Minerals; Osteogenesis, | 2001 |
Osteoporosis and bone marrow mastocytosis: dissociation of skeletal responses and mast cell activity during long-term bisphosphonate therapy.
Topics: Bone Density; Diphosphonates; Humans; Male; Mast Cells; Mastocytosis; Middle Aged; Osteoporosis; Pam | 2002 |
A pharmacokinetic and pharmacodynamic model for intravenous bisphosphonate (pamidronate) in osteoporosis.
Topics: Adult; Aged; Bone Resorption; Diphosphonates; Female; Humans; Hydroxyproline; Male; Middle Aged; Mod | 2002 |
[Bone evaluation in ten adults with cutaneous mastocytosis].
Topics: Adult; Anti-Inflammatory Agents; Bone Density; Bone Diseases; Bone Diseases, Metabolic; Bone Marrow | 2002 |
Intravenous pamidronate in the treatment of osteoporosis associated with corticosteroid dependent lung disease: an open pilot study.
Topics: Adult; Aged; Asthma; Bone Density; Cervical Vertebrae; Diphosphonates; Female; Femur; Fractures, Spo | 1992 |
Pamidronate.
Topics: Clinical Trials as Topic; Diphosphonates; Humans; Hypercalcemia; Hyperparathyroidism; Neoplasms; Ost | 1992 |
Estrogen maintains trabecular bone volume in rats not only by suppression of bone resorption but also by stimulation of bone formation.
Topics: Animals; Bone Resorption; Diphosphonates; Disease Models, Animal; Estradiol; Female; Osteogenesis; O | 1992 |
[Diphosphonates in the treatment of osteoporosis].
Topics: Bone Density; Diphosphonates; Etidronic Acid; Female; Humans; Osteoporosis; Osteoporosis, Postmenopa | 1991 |
Maintained improvement in calcium balance and bone mineral content in patients with osteoporosis treated with the bisphosphonate APD.
Topics: Adult; Aged; Bone and Bones; Calcium; Diphosphonates; Female; Humans; Male; Middle Aged; Minerals; O | 1989 |
Relapse of osteoporosis circumscripta as a lytic ring after treatment of Paget's disease with intravenous 3-amino-1-hydroxypropylidene-1,1-bisphosphonate.
Topics: Adult; Diphosphonates; Female; Humans; Injections, Intravenous; Osteitis Deformans; Osteoporosis; Pa | 1988 |
Characteristics and bisphosphonate treatment of a patient with juvenile osteoporosis.
Topics: Adolescent; Calcitriol; Calcium; Diphosphonates; Humans; Hydroxyproline; Intestinal Absorption; Male | 1985 |